

www.apple2023.org



The 13th Asia-Pacific Primary Liver Cancer Expert Meeting

Novel Insights into the Evolution of Liver Cancer Management

July 6-8, 2023 | Grand InterContinental Seoul Parnas, Seoul, Korea





CONTENTS

- 01 Welcome Message
- 02 Organizing Committee
- 04 Invited Faculty
- 06 Floor Plan
- 07 Industrial Exhibition Floor Plan
- 08 General Information

APPLE

WELCOME MESSAGE

Dear Colleagues and Friends,

On behalf of the organizing committee of the 13th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2023), we would like to welcome you to the annual conference, which will be held on July 6–8, 2023, at the Grand InterContinental Seoul Parnas in Seoul, Korea.

We are excited to announce that the venue for the APPLE Meeting returns to Korea in 2023, after the 9th APPLE Meeting which was held in Seoul in 2018. Following the great success of the previous APPLE meetings hosted by various countries, it is our hope that this meeting will also serve as an important platform for sharing valuable research results for the treatment of liver cancer.

Under the theme of “Novel Insights into the Evolution of Liver Cancer Management,” APPLE 2023 will focus on fostering and promoting intellectual collaboration and exchange between physicians, scientists, and industry leaders that will lead to common discussions pertaining to the latest advanced innovations in Liver Cancer Treatment.

We will provide all the participants with an excellent opportunity to engage in a dialogue with distinguished scholars and experts as well as industry leaders so they can play a crucial role in developing solutions to the most pressing issues in Liver Cancer, generating another consensus on various perspectives of its treatment that will build a brighter today and tomorrow in our profession.

Thank you.



Young Nyun Park
Hosting Chairperson
APPLE 2023



Kwang Cheol Koh
Hosting Co-Chairperson
APPLE 2023



Hyunchul Rhim
Hosting Co-Chairperson
APPLE 2023



Jong Young Choi
Hosting Co-Chairperson
APPLE 2023



Norihiro Kokudo
President
The APPLE Association

ORGANIZING COMMITTEE

GOVERNING BOARD of the APPLE Association

President

Norihiro Kokudo (Tokyo)

Secretary General

Chih-Hung Hsu (Taipei)

Vice Secretary General

Do Young Kim (Seoul)

Treasurer

Jian Zhou (Shanghai)

Scientific Committee Chair

Irene Oi-Lin Ng (Hong Kong)

Masafumi Ikeda (Kashiwa)

Publication Chair

Michiie Sakamoto (Tokyo)

Kyung-Suk Suh (Seoul)

Education Chair

Chiun Hsu (Taipei)

Pierce Chow (Singapore)

Advisor

Kwang-Hyub Han (Seoul)

Masatoshi Kudo (Osaka)

Ann-Lii Cheng (Taipei)

Sheng-Long Ye (Shanghai)

Jinsil Seong (Seoul)

Council

Kengo Yoshimitsu (Fukuoka)

Masayuki Kurosaki (Tokyo)

Etsuro Hatano (Kyoto)

Ying-Hong Shi (Shanghai)

Yinghua Zou (Beijing)

Minshan Chen (Shanghai)

Thomas Yau (Hong Kong)

Jin Wook Chung (Seoul)

Yong Han Paik (Seoul)

Young Nyun Park (Seoul)

Jason Chia-Hsien Cheng (Taipei)

Naomi Khaing Than Hlaing (Yangon)

Ghassan Abou-Alfa (New York)

Linda Wong (Honolulu)

Andrew X. Zhu (Shanghai/Boston)

ORGANIZING COMMITTEE

LOCAL ORGANIZING COMMITTEE (APPLE 2023)

Hosting Chairperson	Advisor
Young Nyun Park (Yonsei Univ.)	Kwang-Hyub Han (CHA Univ.)
Hosting Co-Chairperson	Yun Hwan Kim (Korea Univ.)
Kwang Cheol Koh (Sungkyunkwan Univ.)	Kwan Sik Lee (CHA Univ.)
Hyunchul Rhim (Sungkyunkwan Univ.)	Seung Woon Paik (Sungkyunkwan Univ.)
Jong Young Choi (The Catholic Univ. of Korea)	Kyung-Suk Suh (Seoul National Univ.)
Secretary General	Jinsil Seong (Yonsei Univ.)
Do Young Kim (Yonsei Univ.)	Joong-Won Park (National Cancer Center)
Scientific Committee	Seung-Kew Yoon (The Catholic Univ. of Korea)
Kang Mo Kim (Univ. of Ulsan)	Jin Wook Chung (Seoul National Univ.)
Publication	Si Hyun Bae (The Catholic Univ. of Korea)
Haeryoung Kim (Seoul National Univ.)	Young Kyung You (The Catholic Univ. of Korea)
Social/Liaison	Ki-Hun Kim (Univ. of Ulsan)
Hyung Joon Kim (Chung-Ang Univ.)	Scientific Committee
Information	Kang Mo Kim (Univ. of Ulsan), Chair
Tae Hyun Kim (National Cancer Center)	Bo Hyun Kim (National Cancer Center)
International Cooperation	Jonggi Choi (Univ. of Ulsan)
Ju Hyun Shim (Univ. of Ulsan)	Ho Joong Choi (The Catholic Univ. of Korea)
Public Relations	Sae Byeol Choi (Korea Univ.)
Joon-Il Choi (The Catholic Univ. of Korea)	Jinhong Jung (Univ. of Ulsan)
Exhibition	Wonseok Kang (Sungkyunkwan Univ.)
Jongman Kim (Sungkyunkwan Univ.)	Haeryoung Kim (Seoul National Univ.)
Planning	Hye Won Lee (Yonsei Univ.)
Su Jong Yu (Seoul National Univ.)	In Joon Lee (National Cancer Center)
Treasurer	Hyungjin Rhee (Yonsei Univ.)
Bo Hyun Kim (National Cancer Center)	Changhoon Yoo (Univ. of Ulsan)
Wonseok Kang (Sungkyunkwan Univ.)	Su Jong Yu (Seoul National Univ.)
Vice-Secretary General	
Hyun Woong Lee (Yonsei Univ.)	
Sung Won Lee (The Catholic Univ. of Korea)	

INVITED FACULTY

Americas			
Morris Sherman	<i>Univ. Health Network</i>	Takahiro Kodama	<i>Osaka Univ.</i>
Linda Wong	<i>Univ. of Hawaii</i>	Norihiro Kokudo	<i>National Center for Global Health and Medicine</i>
Ghassan Abou-Alfa	<i>Memorial Sloan Kettering Cancer Center</i>	Masatoshi Kudo	<i>Kindai Univ.</i>
Christopher Crane	<i>Memorial Sloan Kettering Cancer Center</i>	Masayuki Kurosaki	<i>Musashino Red Cross Hospital</i>
Richard S. Finn	<i>Univ. of California Los Angeles</i>	Zenichi Morise	<i>Fujita Health Univ.</i>
Kathryn J. Fowler	<i>Univ. of California San Diego</i>	Takamichi Murakami	<i>Kobe Univ.</i>
Edward Kim	<i>Icahn School of Medicine at Mount Sinai</i>	Eiichi Ogawa	<i>Kyushu Univ.</i>
Augusto Villanueva	<i>Icahn School of Medicine at Mount Sinai</i>	Michiie Sakamoto	<i>Keio Univ.</i>
Xin Wei Wang	<i>National Institutes of Health</i>	Yo-ichi Yamashita	<i>Aso Iizuka Hospital</i>
Australia		Kengo Yoshimitsu	<i>Fukuoka Univ.</i>
Ankur Sharma	<i>Harry Perkins Institute of Medical Research</i>	Valerie Chew	<i>Duke-NUS Medical School</i>
Europe		Pierce Chow	<i>National Cancer Centre Singapore</i>
Julien Calderaro	<i>Henri Mondor Univ. Hospital</i>	Ah-Jung Jeon	<i>Mirxes</i>
Peter Schirmacher	<i>Heidelberg Univ.</i>	Han Chong Toh	<i>National Cancer Centre Singapore</i>
Fabio Piscaglia	<i>Univ. of Bologna</i>	Li-Tzong Chen	<i>Kaoshiung Medical Univ.</i>
Asia		Ann-Lii Cheng	<i>National Taiwan Univ.</i>
Ying-Hong Shi	<i>Fudan Univ.</i>	Jason Chia-Hsien Cheng	<i>National Taiwan Univ.</i>
Xin-Rong Yang	<i>Fudan Univ.</i>	Chiun Hsu	<i>National Taiwan Univ.</i>
Sheng-Long Ye	<i>Fudan Univ.</i>	Chih-Hung Hsu	<i>National Taiwan Univ.</i>
Jian Zhou	<i>Fudan Univ.</i>	Chih-Horng Wu	<i>National Taiwan Univ.</i>
Andrew X. Zhu	<i>I-Mab Biopharma</i>	Sang Hoon Ahn	<i>Yonsei Univ.</i>
Stephen Lam Chan	<i>The Chinese Univ. of Hong Kong</i>	Si Hyun Bae	<i>The Catholic Univ. of Korea</i>
Kenneth Siu Ho Chok	<i>The Univ. of Hong Kong</i>	Jaekyung Cheon	<i>CHA Univ.</i>
Stephanie Ma	<i>The Univ. of Hong Kong</i>	Jaeyoun Cheong	<i>Ajou Univ.</i>
Irene Oi-Lin Ng	<i>The Univ. of Hong Kong</i>	Eunhae Cho	<i>GC Genome</i>
Wai-Kay Seto	<i>The Univ. of Hong Kong</i>	Dongho Choi	<i>Hanyang Univ.</i>
Thomas Yau	<i>The Univ. of Hong Kong</i>	Jin Woo Choi	<i>Seoul National Univ.</i>
Takumi Fukumoto	<i>Kobe Univ.</i>	Jin Young Choi	<i>Yonsei Univ.</i>
Etsuro Hatano	<i>Kyoto Univ.</i>	Jong Young Choi	<i>The Catholic Univ. of Korea</i>
Masafumi Ikeda	<i>National Cancer Center Hospital East</i>	Joon-Il Choi	<i>The Catholic Univ. of Korea</i>
Toru Ikegami	<i>The Jikei Univ. School of Medicine</i>	Kyungho Choi	<i>Seoul National Univ.</i>
		Moon Seok Choi	<i>Sungkyunkwan Univ.</i>
		Youngrok Choi	<i>Seoul National Univ.</i>
		Jin Wook Chung	<i>Seoul National Univ.</i>


INVITED FACULTY

Geum-Youn Gwak	<i>Sungkyunkwan Univ.</i>	In Joon Lee	<i>National Cancer Center</i>
Chul Ju Han	<i>Korea Cancer Center Hospital</i>	Jeong-Hoon Lee	<i>Seoul National Univ.</i>
Kwang-Hyub Han	<i>CHA Univ.</i>	Jeong Min Lee	<i>Seoul National Univ.</i>
Jae Seok Hwang	<i>Keimyung Univ.</i>	Joon Hyoek Lee	<i>Sungkyunkwan Univ.</i>
Shin Hwang	<i>Univ. of Ulsan</i>	Kwan Sik Lee	<i>CHA Univ.</i>
Dongho Hyun	<i>Sungkyunkwan Univ.</i>	Kwang-Woong Lee	<i>Seoul National Univ.</i>
Byoung Kuk Jang	<i>Keimyung Univ.</i>	Seung Soo Lee	<i>Univ. of Ulsan</i>
Jae Young Jang	<i>Soonchunhyang Univ.</i>	Tae-Hee Lee	<i>Konyang Univ.</i>
Jeong Won Jang	<i>The Catholic Univ. of Korea</i>	Ho-Yeong Lim	<i>Sungkyunkwan Univ.</i>
Dong Jin Joo	<i>Yonsei Univ.</i>	Young-Suk Lim	<i>Univ. of Ulsan</i>
Ijin Joo	<i>Seoul National Univ.</i>	Do-Youn Oh	<i>Seoul National Univ.</i>
Dae Won Jun	<i>Hanyang Univ.</i>	Jung Suk Oh	<i>The Catholic Univ. of Korea</i>
Byung Ik Kim	<i>Sungkyunkwan Univ.</i>	Yong Han Paik	<i>Sungkyunkwan Univ.</i>
Chang Wook Kim	<i>The Catholic Univ. of Korea</i>	Hee Chul Park	<i>Sungkyunkwan Univ.</i>
Do Young Kim	<i>Yonsei Univ.</i>	Joong-Won Park	<i>National Cancer Center</i>
Dong-Sik Kim	<i>Korea Univ.</i>	Mi-Suk Park	<i>Yonsei Univ.</i>
Haeryoung Kim	<i>Seoul National Univ.</i>	Young Nyun Park	<i>Yonsei Univ.</i>
Hyo-Cheol Kim	<i>Seoul National Univ.</i>	Hyunchul Rhim	<i>Sungkyunkwan Univ.</i>
Hyung Joon Kim	<i>Chung-Ang Univ.</i>	Baek-Yeol Ryoo	<i>Univ. of Ulsan</i>
Ji Hoon Kim	<i>Korea Univ.</i>	Min-hee Ryu	<i>Univ. of Ulsan</i>
Jin-Wook Kim	<i>Seoul National Univ.</i>	Jinsil Seong	<i>Yonsei Univ.</i>
Jongman Kim	<i>Sungkyunkwan Univ.</i>	Ju Hyun Shim	<i>Univ. of Ulsan</i>
Kyung Sik Kim	<i>Yonsei Univ.</i>	Dong Hyun Sinn	<i>Sungkyunkwan Univ.</i>
Mi Sook Kim	<i>Korea Institute of Radiological & Medical Sciences</i>	Kyung-Suk Suh	<i>Seoul National Univ.</i>
Myeong-Jin Kim	<i>Yonsei Univ.</i>	Won Young Tak	<i>Kyungpook National Univ.</i>
Namkug Kim	<i>Univ. of Ulsan</i>	Jong Yun Won	<i>Yonsei Univ.</i>
Seung Up Kim	<i>Yonsei Univ.</i>	Jong Eun Yeon	<i>Korea Univ.</i>
Soyeon Kim	<i>Univ. of Ulsan</i>	Hyung Joon Yim	<i>Korea Univ.</i>
Tae Hyun Kim	<i>National Cancer Center</i>	Jung-Hwan Yoon	<i>Seoul National Univ.</i>
Yoon Jun Kim	<i>Seoul National Univ.</i>	Sang Min Yoon	<i>Univ. of Ulsan</i>
Young Seok Kim	<i>Soonchunhyang Univ.</i>	Seung-Kew Yoon	<i>The Catholic Univ. of Korea</i>
Kwang Cheol Koh	<i>Sungkyunkwan Univ.</i>	Young Kyoung You	<i>The Catholic Univ. of Korea</i>
Han Chu Lee	<i>Univ. of Ulsan</i>	Hee Chul Yu	<i>Jeonbuk National Univ.</i>
Hye Won Lee	<i>Yonsei Univ.</i>	Su Jong Yu	<i>Seoul National Univ.</i>


FLOOR PLAN

★ QR Code Scanner

5F




2F




INDUSTRIAL EXHIBITION FLOOR PLAN

5F



2F

No.	Jul. 6	Jul. 7	Jul. 8
21	DK Life Science		
22-23	Hanmi		
24	Ono BMS		
25	Ipsen		
26-27	Bukwang		
28-29	Astellas		
30-31	Dong-A ST		
32	Fujirebio		
33	Elekta	Ferring	
34-35	Celltrion		
36	Mitsubishi Tanabe		
37-38	Chong Kung Dang		
39	Olympus		
40-41	SK Plasma		
42	Daewon		
43	Asan		
44	Medtronic		
45	ILDONG		
46	RF Medical		
47	Accuray		



No.	Jul. 6	Jul. 7	Jul. 8
1-3	Daewoong		
4-6	Boston Scientific		
7-9	Boryung		
10-12	Samil		
13-14	Abbvie		
15-17	GC		
18-20	Roche Diagnostics		

GENERAL INFORMATION

The 13th Asia-Pacific Primary Liver Cancer Expert Meeting

- Date July 6-8, 2023
- Venue Grand InterContinental Seoul Parnas, Seoul, Korea
- Theme Novel Insights into the Evolution of Liver Cancer Management
- Official Language English
- Official Website www.apple2023.org
- Hosted by Organizing Committee of APPLE 2023
The APPLE Association
The Korean Liver Cancer Association

Registration Desk

- Location Lobby (2F)
- Opening Hour **July 6** 07:00-16:30 **July 7** 06:30-18:00 **July 8** 06:30-17:00
- Participants will receive their name badges when collecting their meeting materials on site. Participants are required to wear their name badges during all meeting events.

Meal

- Breakfast (All Participant) Breakfast will be served during breakfast sessions.
- Lunch (All Participant) A lunch box will be served during the industry symposium. There will be 3-4 different industry luncheon symposiums held from July 6-8 during lunch time. Please check their agenda in the program book and join the symposium as per your preference.
- Faculty Dinner (Invitation Only) **July 6** 18:00-20:00, Aston House, Walkerhill Hotel
Coach service will be arranged from the Grand InterContinental Seoul Parnas to Aston House. Please come to the main lobby (1F) by 17:00.
- Gala Dinner (All Participant) **July 7** 18:00-20:00, Room AB (Grand Ballroom, 5F)

Opening Ceremony

- Location Room AB (Grand Ballroom, 5F)
- Date & Time **July 7** 10:10-10:20

Award Ceremony & Closing

- Location Room AB (Grand Ballroom, 5F)
- Date & Time **July 8** 16:50-17:20

Poster Presentation

E-Poster Exhibition

- Location Lobby (2F)
- Opening Hour July 7 07:00-18:00 July 8 07:00-17:00

Oral Poster Presentation

- Location Room E (Chrysanthemum, 2F)
- Presentation Date & Time July 7 16:20-17:20

Preview Room

- Location Wisteria (2F), Preview Room (5F)
- Opening Hour July 6 07:00-16:30 July 7 06:00-18:00 July 8 06:00-17:00
- All presenters are requested to come to the Preview Room at least 1 hour in advance of the presentations to verify if the data function properly on the equipment provided.

Faculty Lounge

Location & Opening Hour

- Flora (5F) July 6 08:00-16:00
- Maple (5F) July 7 07:00-18:00 July 8 07:00-17:00

Industrial Exhibition

- Location Grand Ballroom Lobby (5F), Orchid (2F), Chrysanthemum (2F)
- Opening Hour July 6 08:30-16:40 July 7 08:30-18:00 July 8 08:30-17:00

Useful Phone Numbers

- 119 Emergency (Fire & Ambulance)
- 112 Police
- 1330 Foreign Traveller Hotline

평점안내

대한의사협회평점: 1일 최대 6점 (총 18점 이수 가능)

대한내과학회 내과전문의 평생교육평점: 1일 최대 1점 (최고 3점 이수 가능)



CONTENTS

- 12 APPLE Academy Program at a Glance
- 13 APPLE Academy Scientific Program
- 15 Program at a Glance
- 16 Scientific Program
- 29 Oral Poster Presentation
- 31 E-Poster Exhibition



The Asia-Pacific Primary Liver Cancer Expert Association (APPLE)

The Asia-Pacific Primary Liver Cancer Expert (APPLE) Association was established in 2013.

The main objective of the association is to promote the scientific advancement of and education in liver cancer management in the Asia-Pacific region, where 80% of global liver cancer deaths occur, including the exchange of information and the development of consensus in the field of liver cancer.

The APPLE convened for the first time in 2010 and was attended by professionals who have abundant clinical experience in medical treatment of liver cancer in the Asia Pacific region. It was our hope that this meeting would be of substantial help to liver cancer treatments through the exchange of their clinical experience and knowledge.


At the same time, by inviting internationally renowned experts in the field of liver cancer, we intended to determine the procedure for officially and internationally recognizing the treatment presently being practiced at clinics in the Asia Pacific region.

We also sought to introduce new clinical studies now in progress in the field of liver cancer to overcome the problems yet unsolved and join forces with them to explore new roads.

*Novel Insights into the Evolution of
Liver Cancer Management*



PROGRAM AT A GLANCE

July 6 (THU)		
TIME	ROOM C Grand Ballroom 3	ROOM E Chrysanthemum
08:00		
09:00		
10:00	<p>Session 1 Changes in the Landscape of HCC</p> <p>09:00-10:35</p> <p>Coffee Break</p>	Booth Exhibition
11:00	<p>Session 2 Translational and Basic Research That May Impact on the Clinical Management of HCC</p> <p>10:50-12:25</p>	
13:00	<p>Luncheon Symposium & Networking</p> 	
14:00	<p>Session 3 Unmet Clinical Need in and Current Clinical Research Directions</p> <p>13:30-15:05</p> <p>Coffee Break</p>	
15:00		
16:00	<p>Session 4 From APPLE Academy into the Future</p> <p>15:20-16:40</p>	
17:00		
18:00		
19:00	<p>Faculty Dinner (Invitation Only)</p> <p>18:00-20:00</p>	
20:00		



APPLE ACADEMY 2023

July 6 (Thu.), 2023 | Room C (Grand Ballroom 3)



08:50-09:00 Opening Remarks

Pierce Chow (National Cancer Centre Singapore, Singapore)

Session 1. Changes in the Landscape of HCC

Kwang-Hyub Han (CHA Univ., Seoul), Kengo Yoshimitsu (Fukuoka Univ., Fukuoka)

09:00-09:20 Changing Etiology and Epidemiology of HCC: Asia and Worldwide

Do Young Kim (Yonsei Univ., Seoul)

09:20-09:40 New Concepts in the Imaging Diagnosis of HCC:
Can Artificial Intelligence Help?

Chih-Hong Wu (National Taiwan Univ., Taipei)

09:40-10:00 Molecular Heterogeneity in HCC and the Challenge of
Identifying Predictive Biomarkers

*Irene Oi-Lin Ng
(The Univ. of Hong Kong, Hong Kong)*

10:00-10:20 Adaptation of Practice Guidelines: When East Meets West

*Li-Tzong Chen
(Kaohsiung Medical Univ., Kaohsiung)*

10:20-10:35 Q&A

10:35-10:50 Coffee Break

Session 2. Translational and Basic Research That May Impact on the Clinical Management of HCC

Pierce Chow (National Cancer Centre Singapore, Singapore), Chiun Hsu (National Taiwan Univ., Taipei)

10:50-11:10 Biomarker-Based Precision Pharmacotherapy in HCC

Takahiro Kodama (Osaka Univ., Osaka)

11:10-11:30 Translational Research: The Impact from Research in Epigenomics

Ah-Jung Jeon (Mirixes, Singapore)

11:30-11:50 Translational Research: The Impact from Research
in Spatial Transcriptomics

*Ankur Sharma
(Harry Perkins Institute of Medical Research, Perth)*

11:50-12:10 The Promise of Immuno-Neoadjuvant Therapy in HCC

*Han Chong Toh
(National Cancer Centre Singapore, Singapore)*

12:10-12:25 Q&A

12:25-13:30 Luncheon Symposium & Networking



APPLE ACADEMY 2023

July 6 (Thu.), 2023 | Room C (Grand Ballroom 3)



Session 3. Unmet Clinical Need in and Current Clinical Research Directions

Etsuro Hatano (Kyoto Univ., Kyoto), Thomas Yau (The Univ. of Hong Kong, Hong Kong)







13:30-13:50	Early HCC and Treatment with Curative Intent - Has Adjuvant Therapy Opened a New Paradigm?	<i>Linda Wong (Univ. of Hawaii, Honolulu)</i>
13:50-14:10	Intermediate-Stage HCC: Re-Defining the Role of Liver-Directed Therapy	<i>Hyo-Cheol Kim (Seoul National Univ., Seoul)</i>
14:10-14:30	Intermediate-Stage HCC: Expanding the Role of Systemic Therapy	<i>Masafumi Ikeda (National Cancer Center Hospital East, Kashiwa)</i>
14:30-14:50	Advanced HCC: Beyond IMbrave150 and HIMALAYA	<i>Chih-Hung Hsu (National Taiwan Univ., Taipei)</i>
14:50-15:05	Q&A	
15:05-15:20	Coffee Break	

Session 4. From APPLE Academy into the Future

Masatoshi Kudo (Kindai Univ., Osaka), Jian Zhou (Fudan Univ., Shanghai)

15:20-15:45	Investigator-Initiated Trials for HCC in the Asia-Pacific Region	<i>Pierce Chow (National Cancer Centre Singapore, Singapore)</i>
15:45-16:05	APPLE Association as a Platform for Future International Research Collaboration	<i>Kwang-Hyub Han (CHA Univ., Seoul)</i>
16:05-16:25	Promoting the Next-Generation Liver Cancer Experts to the Global Arena	<i>Ann-Lii Cheng (National Taiwan Univ., Taipei)</i>
16:25-16:40	Q&A	
16:40-16:45	Closing Remarks	<i>Norihiro Kokudo (National Center for Global Health and Medicine, Tokyo)</i>

PROGRAM AT A GLANCE

July 7 (FRI)						
TIME	ROOM AB Grand Ballroom 1+2	ROOM C Grand Ballroom 3	ROOM 1 Iris	ROOM 2 Camelia	ROOM 3 Lotus	ROOM D Orchid Chrysanthemum
07:00						
08:00		Breakfast Symposium 1  DAEWOONG 07:40-08:20	[EMW 1] Systemic Therapy: Case Presentation 07:20-08:20	[EMW 2] Radiologic Assessment 07:20-08:20	[EMW 3] Surgical Strategy to Tumor Biology 07:20-08:20	07:40-08:20 Breakfast Symposium 2 
09:00	Session 1 Surveillance and Imaging Diagnosis for HCC 08:30-10:00	Parallel Session 1 From Bench to Bedside and Beyond 08:30-10:00				Booth Exhibition
10:00	Coffee Break & Opening Ceremony					
	State-of-the-Art Lecture 1 10:20-10:50					
11:00	Session 2 Evolving Management of Early HCC 11:00-12:30	Parallel Session 2 APPLE-KLCA Joint Symposium: Virus and HCC 11:00-12:30				
13:00	Luncheon Symposium 1 	Luncheon Symposium 2 	Luncheon Symposium 3 			Luncheon Symposium 4 
14:00	Presidential Lecture 13:30-14:00					Booth Exhibition
15:00	Session 3 New Trends in Management of Intermediate-Stage HCC 14:00-15:30	Parallel Session 3 Debatable Topics in HCC 14:00-15:30				
16:00	Coffee Break & Poster Viewing					
	State-of-the-Art Lecture 2 15:50-16:20					
17:00		Session 4 Tumor Board: Multidisciplinary Approach 16:20-17:50				Oral Poster Session 16:20-17:20
18:00						
19:00	Gala Dinner (APPLE General Meeting) 18:00-20:00					
20:00						

SCIENTIFIC PROGRAM

ROOM AB

Grand Ballroom 1+2 (5F)

Session 1. Surveillance and Imaging Diagnosis for HCC

Morris Sherman (Univ. Health Network, Toronto), Kwan Sik Lee (CHA Univ., Seongnam), Kengo Yoshimitsu (Fukuoka Univ., Fukuoka)

08:30-08:50 Screening for HCC: From Here to Where? *Morris Sherman (Univ. Health Network, Toronto)*

08:50-09:10 Emerging Imaging Tools for HCC Surveillance: Benefits and Concerns *Kengo Yoshimitsu (Fukuoka Univ., Fukuoka)*

09:10-09:30 Diagnostic Strategy and Risk Stratification of Borderline Nodules on Imaging: Emphasis on OATP Transporters, Hemodynamic Changes, and Advanced Imaging Techniques *Jeong Min Lee (Seoul National Univ., Seoul)*

09:30-09:50 Developing Biomarkers for Early Detection of HCC *Stephen Lam Chan (The Chinese Univ. of Hong Kong, Hong Kong)*

09:50-10:00 Discussion

10:00-10:10 Coffee Break

10:10-10:20 Opening Ceremony

State-of-the-Art Lecture 1

Takamichi Murakami (Kobe Univ., Kobe)

10:20-10:50 When We Should Consider the Biopsy for Diagnosis, Subtyping, and Prognostication of Primary Liver Cancer: Radiologist's Perspective *Kathryn J. Fowler (Univ. of California San Diego, San Diego)*

Session 2. Evolving Management of Early HCC

Pierce Chow (National Cancer Centre Singapore, Singapore), Seung-Kew Yoon (The Catholic Univ. of Korea, Seoul), Yoon Jun Kim (Seoul National Univ., Seoul)

11:00-11:20 Advances in Surgical Management and Evolving Techniques *Pierce Chow (National Cancer Centre Singapore, Singapore)*

11:20-11:40 Local Ablation: What's New in 2023? *Hyunchul Rhim (Sungkyunkwan Univ., Seoul)*

11:40-12:00 Ablative Radiotherapy for Early HCC *Jason Chia-Hsien Cheng (National Taiwan Univ., Taipei)*

12:00-12:20 Role of Transarterial Therapy in Early HCC *Hyo-Cheol Kim (Seoul National Univ., Seoul)*

12:20-12:30 Discussion

12:30-13:30 Luncheon Symposium 1



SCIENTIFIC PROGRAM

ROOM AB

Grand Ballroom 1+2 (5F)

Presidential Lecture

Kyung-Suk Suh (Seoul National Univ., Seoul)

13:30-14:00 Evolution of APPLE and Liver Cancer Management

Norihiro Kokudo (National Center for Global Health and Medicine, Tokyo)

Session 3. New Trends in Management of Intermediate-Stage HCC

Fabio Piscaglia (Univ. of Bologna, Bologna), Masatoshi Kudo (Kindai Univ., Osaka), Jong Young Choi (The Catholic Univ. of Korea, Seoul)

14:00-14:20 Looking into the Intermediate-Stage HCC: Ongoing Effort towards Creating a Subclassification

Fabio Piscaglia (Univ. of Bologna, Bologna)

14:20-14:40 Expanding the Role of Surgical Resection and Transplantation in Intermediate-Stage HCC

Jongman Kim (Sungkyunkwan Univ., Seoul)

14:40-15:00 To What Extent Can TARE Replace the Role of TACE in the Intermediate-Stage HCC?

Edward Kim (Icahn School of Medicine at Mount Sinai, New York)

15:00-15:20 The Potential Role of Systemic Therapy in Intermediate-Stage HCC: A Paradigm Shift?

Masatoshi Kudo (Kindai Univ., Osaka)

15:20-15:30 Discussion

15:30-15:50 Coffee Break & Poster Viewing

State-of-the-Art Lecture 2

Joong-Won Park (National Cancer Center, Goyang)

15:50-16:20 Systemic Therapies for HCC: Expanding Indications

Ghassan Abou-Alfa (Memorial Sloan Kettering Cancer Center, New York)



SCIENTIFIC PROGRAM

ROOM C

Grand Ballroom 3 (5F)

07:40-08:20 Breakfast Symposium 1  DAEWOONG

Parallel Session 1. From Bench to Bedside and Beyond

Michiie Sakamoto (Keio Univ., Tokyo), Irene Oi-Lin Ng (The Univ. of Hong Kong, Hong Kong), Do Young Kim (Yonsei Univ., Seoul)

08:30-08:50 Deciphering the Immune and Vascular Microenvironment of HCC *Michiie Sakamoto (Keio Univ., Tokyo)*

08:50-09:10 Molecular Landscape of Liver Cancer and Its Clinical Implications *Xin Wei Wang (National Cancer Institute, Bethesda)*

09:10-09:30 Charting Cancer Cell Plasticity in HCC with Multi-Omic Data *Stephanie Ma (The Univ. of Hong Kong, Hong Kong)*

09:30-09:50 Spatial Heterogeneity and Immune Evasion Mechanism of Circulating Tumor Cells in HCC *Xin-Rong Yang (Fudan Univ., Shanghai)*

09:50-10:00 Discussion

10:00-10:20 Coffee Break and Opening Ceremony

State-of-the-Art Lecture 1 ROOM AB

Takamichi Murakami (Kobe Univ., Kobe)

10:20-10:50 When We Should Consider the Biopsy for Diagnosis, Subtyping, and Prognostication of Primary Liver Cancer: Radiologist's Perspective *Kathryn J. Fowler (Univ. of California San Diego, San Diego)*

Parallel Session 2. APPLE-KLCA Joint Symposium: Virus and HCC

Sheng-Long Ye (Fudan Univ., Shanghai), Kwang Cheol Koh (Sungkyunkwan Univ., Changwon), Young-Suk Lim (Univ. of Ulsan, Seoul)

11:00-11:20 Prevention of HBV-Related HCC: Antiviral Therapy *Young-Suk Lim (Univ. of Ulsan, Seoul)*

11:20-11:40 Balancing the Risk and Benefit of Long-Term Antiviral Therapy for HBV *Wai-Kay Seto (The Univ. of Hong Kong, Hong Kong)*

11:40-12:00 Latest Update of Direct-Acting Antiviral Treatment for HCV *Eiichi Ogawa (Kyushu Univ., Fukuoka)*

12:00-12:20 Impact of Direct-Acting Antiviral Therapy on HCC: Occurrence, Recurrence, and Prognosis *Hyung Joon Yim (Korea Univ., Ansan)*

12:20-12:30 Discussion

12:30-13:30 Luncheon Symposium 2  YUHAN

SCIENTIFIC PROGRAM

ROOM C

Grand Ballroom 3 (5F)

Presidential Lecture **ROOM AB**

Kyung-Suk Suh (Seoul National Univ., Seoul)

13:30-14:00 Evolution of APPLE and Liver Cancer Management *Norihiro Kokudo (National Cancer Center for Global Health and Medicine, Tokyo)*

Parallel Session 3. Debatable Topics in HCC

Masayuki Kurosaki (Musashino Red Cross Hospital, Tokyo), Linda Wong (Univ. of Hawaii, Honolulu), Myeong-Jin Kim (Yonsei Univ., Seoul)

14:00-14:20 The Era of Diversity: Does Conventional TACE Still Work? *Jin Wook Chung (Seoul National Univ., Seoul)*

14:20-14:40 Technical Issues in TACE: Focusing on Korean Recommendations *In Joon Lee (National Cancer Center, Goyang)*

14:40-15:00 Role of Surgical Resection for HCC with Portal Vein Tumor Thrombosis *Ying-Hong Shi (Fudan Univ., Shanghai)*

15:00-15:20 Integration of Systemic and Locoregional Therapy in HCC *Joong-Won Park (National Cancer Center, Goyang)*

15:20-15:30 Discussion

15:30-15:50 Coffee Break & Poster Viewing

State-of-the-Art Lecture 2 **ROOM AB**

Joong-Won Park (National Cancer Center, Goyang)

15:50-16:20 Systemic Therapies for HCC: Expanding Indications *Ghassan Abou-Alfa (Memorial Sloan Kettering Cancer Center, New York)*

Session 4. Tumor Board: Multidisciplinary Approach

Kyung-Suk Suh (Seoul National Univ., Seoul), Han Chu Lee (Univ. of Ulsan, Seoul)

16:20-17:40 Case 1, 2, 3, 4 *Su Jong Yu (Seoul National Univ., Seoul)*



Live online voting is available. Please scan the QR code and share your opinion during the session.

Join at Slido.com #1450 531

17:40-17:50 Discussant: *Joong-Won Park (National Cancer Center, Goyang), Thomas Yau (The Univ. of Hong Kong, Hong Kong), Jinsil Seong (Yonsei Univ., Seoul), Pierce Chow (National Cancer Centre Singapore, Singapore), Edward Kim (Icahn School of Medicine at Mount Sinai, New York)*

EARLY MORNING WORKSHOP

JULY 7 (FRI.)

ROOM 1

Iris (2F)

Systemic Therapy: Case Presentation

Ghassan Abou-Alfa (Memorial Sloan Kettering Cancer Center, New York), Jae Young Jang (Soonchunhyang Univ., Seoul)

07:20-07:40 Management of Adverse Events in Patients Receiving Immunotherapy (Case Sharing) *Jaekyung Cheon (CHA Univ., Seongnam)*

07:40-08:00 Management of Adverse Events in Patients Receiving TKI (Case Sharing) *Hye Won Lee (Yonsei Univ., Seoul)*

Discussants

08:00-08:20 *Thomas Yau (The Univ. of Hong Kong, Hong Kong)*
Stephen Lam Chan (The Chinese Univ. of Hong Kong, Hong Kong)
Baek-Yeol Ryoo (Univ. of Ulsan, Seoul), Jeong Won Jang (The Catholic Univ. of Korea, Seoul)

ROOM 2

Camelia (2F)

Radiologic Assessment of Response to Locoregional Treatment for HCC

Kathryn J. Fowler (Univ. of California San Diego, San Diego), Jeong Min Lee (Seoul National Univ., Seoul)

07:20-07:40 LI-RADS Treatment Response Algorithm *Kathryn J. Fowler (Univ. of California San Diego, San Diego)*

07:40-08:00 Novel Imaging Technique for HCC Response Evaluation *Ijin Joo (Seoul National Univ., Seoul)*

Discussants

08:00-08:20 *Joon-Il Choi (The Catholic Univ. of Korea, Seoul), Byoung Kuk Jang (Keimyung Univ., Daegu)*
Soyeon Kim (Univ. of Ulsan, Seoul), Dong Hyun Sinn (Sungkyunkwan Univ., Seoul)

ROOM 3

Lotus (2F)

Changes in Surgical Strategy for HCC according to Tumor Biology

Yo-ichi Yamashita (Aso Iizuka Hospital, Fukuoka), Hee Chul Yu (Jeonbuk National Univ., Jeonju)





07:20-07:40 Changes in Resection Concepts Based on the Microvascular Invasion for Early HCC *Yo-ichi Yamashita (Aso Iizuka Hospital, Fukuoka)*

07:40-08:00 Liver Transplantation Strategy according to Tumor Biology *Youngrok Choi (Seoul National Univ., Seoul)*

Discussants

08:00-08:20 *Kenneth Siu Ho Chok (The Univ. of Hong Kong, Hong Kong), Jong Yun Won (Yonsei Univ., Seoul)*
Dong-Sik Kim (Korea Univ., Seoul), Kwang-Woong Lee (Seoul National Univ., Seoul)

PROGRAM AT A GLANCE

July 8 (SAT)							
TIME	ROOM AB Grand Ballroom 1+2	ROOM C Grand Ballroom 3	ROOM 1 Iris	ROOM 2 Camelia	ROOM 3 Lotus	ROOM D Orchid	ROOM E Chrysanthemum
07:00							
08:00		Breakfast Symposium 3  07:40-08:20	[EMW 1] TACE 07:20-08:20	[EMW 2] Radiotherapy 07:20-08:20	[EMW 3] Molecular Classification 07:20-08:20		
09:00	Session 5 Optimal Strategy for Systemic Therapy for Advanced HCC 08:30-10:00	Parallel Session 4 Application of Artificial Intelligence in Liver Cancer 08:30-10:00				Booth Exhibition	Poster & Booth Exhibition
10:00	Coffee Break & Poster Viewing						
11:00	State-of-the-Art Lecture 3 10:20-11:00						
12:00	Session 6 A Deep Dive into the Era of Immuno-Oncology 11:00-12:30	Parallel Session 5 A New Era of Liver Transplantation Oncology 11:00-12:30					
13:00	Luncheon Symposium 5 	Luncheon Symposium 6 				Luncheon Symposium 7 	
14:00	Session 7 Emerging Therapy and Precision Medicine 13:30-15:00	Parallel Session 6 Recent Advance of Surgical Resection for HCC 13:30-15:00				Booth Exhibition	
15:00	Coffee Break & Poster Viewing						
16:00	Session 8 Recent Updates of Intrahepatic Cholangiocarcinoma 15:20-16:50	Parallel Session 7 Various Classification of Liver Cancer towards Precision Medicine 15:20-16:50					
17:00	Summary of APPLE 2023 Award & Closing Ceremony						
18:00							

SCIENTIFIC PROGRAM

ROOM AB

Grand Ballroom 1+2 (5F)

Session 5. Optimal Strategy for Systemic Therapy for Advanced HCC

*Andrew X. Zhu (I-Mab Biopharma, Shanghai), Ann-Lii Cheng (National Taiwan Univ., Taipei),
Si Hyun Bae (The Catholic Univ. of Korea, Seoul)*

08:30-08:50	Optimal First-Line Therapy for HCC	<i>Baek-Yeol Ryoo (Univ. of Ulsan, Seoul)</i>
08:50-09:10	Optimal Subsequent Option after First-Line Immuno-Oncology Therapy in Advanced HCC	<i>Andrew X. Zhu (I-Mab Biopharma, Shanghai)</i>
09:10-09:30	Optimal Subsequent Options after First-Line Multi-Kinase Inhibitor Therapy for Advanced HCC	<i>Chih-Hung Hsu (National Taiwan Univ., Taipei)</i>
09:30-09:50	Matching the Right Agents with the Right Patients for the Management of HCC: Biomarkers for Systemic Therapy	<i>Thomas Yau (The Univ. of Hong Kong, Hong Kong)</i>
09:50-10:00	Discussion	
10:00-10:20	Coffee Break & Poster Viewing	


State-of-the-Art Lecture 3

Kwang-Hyub Han (CHA Univ., Seoul)

10:20-11:00	Update on the Molecular-Pathological Features of HCC and Cholangiocarcinoma	<i>Young Nyun Park (Yonsei Univ., Seoul)</i>
-------------	-----------------------------------------------------------------------------	----------------------------------------------

Session 6. A Deep Dive into the Era of Immuno-Oncology

*Richard S. Finn (Univ. of California Los Angeles, LA), Won Young Tak (Kyungpook National Univ., Daegu),
Ho-Yeong Lim (Sungkyunkwan Univ., Seoul)*

11:00-11:20	Trajectory of Immune Evolution and Mechanism of Response to Immunotherapy in HCC	<i>Valerie Chew (Duke-NUS Medical School, Singapore)</i>
11:20-11:40	Rechallenging of Immuno-Oncology Treatment after Complications: Can It Be Done Safely?	<i>Stephen Lam Chan (The Chinese Univ. of Hong Kong, Hong Kong)</i>
11:40-12:00	Neo-Adjuvant or Adjuvant Immunotherapy in HCC: Where Are We Now?	<i>Ann-Lii Cheng (National Taiwan Univ., Taipei)</i>
12:00-12:20	Immuno-Oncology in the Treatment of HCC: Future Perspectives	<i>Richard S. Finn (Univ. of California Los Angeles, LA)</i>
12:20-12:30	Discussion	
12:30-13:30	Luncheon Symposium 5 	

SCIENTIFIC PROGRAM

ROOM AB

Grand Ballroom 1+2 (5F)

Session 7. Emerging Therapy and Precision Medicine

*Chiun Hsu (National Taiwan Univ., Taipei), Jung-Hwan Yoon (Seoul National Univ., Seoul),
Moon Seok Choi (Sungkyunkwan Univ., Seoul)*

13:30-13:50	Novel Targets in HCC	<i>Augusto Villanueva (Icahn School of Medicine at Mount Sinai, New York)</i>
13:50-14:10	CAR T-Cell Therapy for the Solid Tumors Including HCC: Prospects and Challenges	<i>Kyungho Choi (Seoul National Univ. Seoul)</i>
14:10-14:30	Promising Agents in Early Clinical Trials for Unresectable HCC	<i>Masafumi Ikeda (National Cancer Center Hospital East, Kashiwa)</i>
14:30-14:50	Radiation Therapy in HCC: Future Perspectives	<i>Jinsil Seong (Yonsei Univ., Seoul)</i>
14:50-15:00	Discussion	
15:00-15:20	Coffee Break & Poster Viewing	

Session 8. Recent Updates of Intrahepatic Cholangiocarcinoma

*Christopher Crane (Memorial Sloan Kettering Cancer Center, New York), Kyung Sik Kim (Yonsei Univ., Seoul),
Min-hee Ryu (Univ. of Ulsan, Seoul)*

15:20-15:40	Pathological and Molecular Features of Intrahepatic Cholangiocarcinoma	<i>Peter Schirmacher (Heidelberg Univ., Heidelberg)</i>
15:40-16:00	Surgical Management of Intrahepatic Cholangiocarcinoma: A Comparison with HCC	<i>Etsuro Hatano (Kyoto Univ., Kyoto)</i>
16:00-16:20	Systemic Therapy for Intrahepatic Cholangiocarcinoma: Current and Future Perspectives	<i>Do-Youn Oh (Seoul National Univ., Seoul)</i>
16:20-16:40	The Importance of Local Tumor Control for Inoperable Intrahepatic Cholangiocarcinoma	<i>Christopher Crane (Memorial Sloan Kettering Cancer Center, New York)</i>
16:40-16:50	Discussion	

16:50-17:20 Summary of APPLE 2023 Award & Closing Ceremony

SCIENTIFIC PROGRAM

ROOM C

Grand Ballroom 3 (5F)

07:40-08:20 Breakfast Symposium 3 

Parallel Session 4. Application of Artificial Intelligence (AI) in Liver Cancer

Julien Calderaro (Henri Mondor Univ. Hospital, Créteil), Yong Han Paik (Sungkyunkwan Univ., Seoul), Namkug Kim (Univ. of Ulsan, Seoul)

08:30-08:50 AI-Based Cancer Screening Using Liquid Biopsy *Eunhae Cho (GC Genome, Yongin)*

08:50-09:10 Qualitative and Quantitative Imaging Biomarkers to Predict Prognosis of HCC *Seung Soo Lee (Univ. of Ulsan, Seoul)*

09:10-09:30 AI Based Pathology: A New Generation of Biomarkers for HCC *Julien Calderaro (Henri Mondor Univ. Hospital, Créteil)*

09:30-09:50 Predicting HCC Risk Using Artificial Intelligence *Jeong-Hoon Lee (Seoul National Univ., Seoul)*

09:50-10:00 Discussion

10:00-10:20 Coffee Break & Poster Viewing

State-of-the-Art Lecture 3

ROOM AB

Kwang-Hyub Han (CHA Univ., Seoul)

10:20-11:00 Update on the Molecular-Pathological Features of HCC and Cholangiocarcinoma *Young Nyun Park (Yonsei Univ., Seoul)*

Parallel Session 5. A New Era of Liver Transplantation Oncology

Norihiro Kokudo (National Center for Global Health and Medicine, Tokyo), Kenneth Siu Ho Chok (The Univ. of Hong Kong, Hong Kong), Young Kyoung You (The Catholic Univ. of Korea, Seoul)

11:00-11:20 Extended Criteria for Liver Transplantation in HCC *Toru Ikegami (The Jikei Univ. School of Medicine, Tokyo)*

11:20-11:40 Down-Staging and Waiting Times for Liver Transplantation in Advanced HCC *Dong Jin Joo (Yonsei Univ., Seoul)*

11:40-12:00 The Role of Transplantation in Combined Hepatocellular-Cholangiocarcinoma *Linda Wong (Univ. of Hawaii, Honolulu)*

12:00-12:20 Multidisciplinary Approach for Post-Liver Transplantation Recurrence *Kenneth Siu Ho Chok (The Univ. of Hong Kong, Hong Kong)*

12:20-12:30 Discussion

12:30-13:30 Luncheon Symposium 6 

SCIENTIFIC PROGRAM

ROOM C

Grand Ballroom 3 (5F)

Parallel Session 6. Recent Advance of Surgical Resection for HCC: Expanding the Surgical Indication

Takumi Fukumoto (Kobe Univ., Kobe), Jae Seok Hwang (Keimyung Univ., Daegu), Shin Hwang (Univ. of Ulsan, Seoul)

13:30-13:50	Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS) for Unresectable HCC	<i>Jian Zhou (Fudan Univ., Shanghai)</i>
13:50-14:10	Surgical Resection of Multiple HCC	<i>Shin Hwang (Univ. of Ulsan, Seoul)</i>
14:10-14:30	Surgical Resection for Intrahepatic and Extrahepatic Recurrent HCC	<i>Etsuro Hatano (Kyoto Univ., Kyoto)</i>
14:30-14:50	Laparoscopic Repeated Liver Resection for Recurrent HCC	<i>Zenichi Morise (Fujita Health Univ., Toyoake)</i>
14:50-15:00	Discussion	
15:00-15:20	Coffee Break & Poster Viewing	

Parallel Session 7. Various Classification of Liver Cancer towards Precision Medicine

Augusto Villanueva (Icahn School of Medicine at Mount Sinai, New York), Young Nyun Park (Yonsei Univ., Seoul), Joon Hyoek Lee (Sungkyunkwan Univ., Seoul)

15:20-15:40	Morphological Classification of HCC and Potential Clinical Implications	<i>Haeryoung Kim (Seoul National Univ., Seoul)</i>
15:40-16:00	Stratification of HCC : Cellular, Molecular and Blood-Based Biomarkers	<i>Irene Oi-Lin Ng (The Univ. of Hong Kong, Hong Kong)</i>
16:00-16:20	Correlation of Imaging and Molecular-Pathologic Subtypes of HCC	<i>Jin-Young Choi (Yonsei Univ., Seoul)</i>
16:20-16:40	Biopsy for HCC: Tissue or Liquid?	<i>Xin-Rong Yang (Fudan Univ., Shanghai)</i>
16:40-16:50	Discussion	

EARLY MORNING WORKSHOP

JULY 8 (SAT)

ROOM 1

Iris (2F)

TACE for HCC: Technical Recommendations of the Korea Liver Cancer Association

Jin Wook Chung (Seoul National Univ., Seoul), Edward Kim (Icahn School of Medicine at Mount Sinai, New York)

07:20-07:40 Superselective TACE Using Ethiodized Oil Emulsions and Drug-Eluting Beads in Korea *Jin Woo Choi (Seoul National Univ., Seoul)*

07:40-07:55 Technical Issues of cTACE *Dongho Hyun (Sungkyunkwan Univ., Seoul)*

07:55-08:10 Technical Issues of DEB-TACE *Jung Suk Oh (The Catholic Univ. of Korea, Seoul)*

Discussants

08:10-08:20 *Young Seok Kim (Soonchunhyang Univ., Bucheon), Geum-Youn Gwak (Sungkyunkwan Univ., Seoul), Jaeyoun Cheong (Ajou Univ., Suwon), Chang Wook Kim (The Catholic Univ. of Korea, Seoul)*

ROOM 2

Camelia (2F)

Radiotherapy as the Best Option at Various Stages

Christopher Crane (Memorial Sloan Kettering Cancer Center, New York), Hee Chul Park (Sungkyunkwan Univ., Seoul)

07:20-07:40 Radiotherapy in Early HCC *Tae Hyun Kim (National Cancer Center, Goyang)*

07:40-08:00 Ablative Radiation for Advanced HCC *Christopher Crane (Memorial Sloan Kettering Cancer Center, New York)*

Discussants

08:00-08:20 *Sang Min Yoon (Univ. of Ulsan, Seoul), Jason Chia-Hsien Cheng (National Taiwan Univ., Taipei), Seung Up Kim (Yonsei Univ., Seoul), Ji Hoon Kim (Korea Univ., Seoul)*

ROOM 3

Lotus (2F)

Liver Cancer Molecular Classification and Its Application

Peter Schirmacher (Heidelberg Univ., Heidelberg), Young Nyun Park (Yonsei Univ., Seoul)

07:20-07:35 The Molecular Classification of HCC and Application of AI *Julien Calderaro (Henri Mondor Univ. Hospital, Créteil)*

07:35-07:50 The Immune Microenvironment of HCC and Its Implication in Immunotherapy *Michiie Sakamoto (Keio Univ., Tokyo)*

07:50-08:05 The Role of Liquid Biopsy in the Prognostication of HCC *Irene Oi-Lin Ng (The Univ. of Hong Kong, Hong Kong)*



08:05-08:20 The Molecular Classification of CCA and Its Application in Clinical Practice *Peter Schirmacher (Heidelberg Univ., Heidelberg)*

INDUSTRY SYMPOSIA FOR BREAKFAST AND LUNCH

July 6 (Thu.), 2023 Luncheon Symposium

 ROOM C Grand Ballroom III	12:25-13:15	Chiun Hsu (National Taiwan Univ., Taipei)
	Evolution in the Treatment Landscape of HCC with Lenvatinib	Yuri Cho (National Cancer Center, Goyang)
	Overview of Treatment Outcome from Clinical Trial to Real World Experience by Focusing on Lenvatinib	Toh Han Chong (National Cancer Centre Singapore, Singapore)

July 7 (Fri.), 2023 Breakfast Symposium


 ROOM C Grand Ballroom III	07:40-08:20	Hyung Jun Kim (Chung-Ang Univ., Seoul)
	Nonalcoholic Fatty Liver Disease	Young Eun Chon (CHA Univ., Seongnam)
 ROOM D Orchid	07:40-08:20	Do Young Kim (Yonsei Univ., Seoul)
	PIVKA II Usefulness and Clinical Performance Study for HCC	Youn Hee Park (Yonsei Univ., Seoul)

July 7 (Fri.), 2023 Luncheon Symposium


 ROOM AB Grand Ballroom I+II	12:30-13:30	Joong Won Park (National Cancer Center, Goyang)
	Igniting Hope: The Dynamic Duo of Tecentriq and Avastin in Revolutionizing HCC Treatment	Su Jong Yu (Seoul National Univ., Seoul)
 ROOM C Grand Ballroom III	12:30-13:30	Jin-Wook Kim (Seoul National Univ., Seongnam)
	Redefine the Opportunity for CHB Early Treatment	Won Mook Choi (Univ. of Ulsan, Seoul)
 ROOM 1 Iris	12:30-13:30	Victor Ho-fun Lee (The Univ. of Hong Kong, Hong Kong)
	Latest Update on HCC Management with SIRT	Edward Kim (Mount Sinai, New York)
 ROOM D Orchid	12:30-13:30	Ann-Lii Cheng (National Taiwan Univ. Taipei), Ju Hyun Shim (Univ. of Ulsan, Seoul)
	Deep Dive into the Lenvatinib - From MOA to the Clinical Outcome -	Ying-Chun Shen (National Taiwan Univ., Taipei)
	The Evolving Role of Multi Kinase Inhibitor Therapy for HCC: Focusing on Lenvatinib	Pil Soo Sung (The Catholic Univ. of Korea, Seoul)


INDUSTRY SYMPOSIA FOR BREAKFAST AND LUNCH

July 8 (Sat.), 2023 Breakfast Symposium

 ROOM C Grand Ballroom III	07:40-08:20	Won Young Tak (Kyungpook National Univ., Daegu)
	Tectentriq+Avastin: Exploring the Real World Experience	Jeong Heo (Pusan National Univ., Busan)

July 8 (Sat.), 2023 Luncheon Symposium

 ROOM AB Grand Ballroom I+II	12:30-13:30	Shi-Ming Lin (Chang Gung Univ., Taipei) Joong-Won Park (National Cancer Center, Goyang)
	Optimizing the Potential of Lenvatinib - "How & When?"	Hideki Iwamoto (Kurume Univ., Japan)

 ROOM C Grand Ballroom III	12:30-13:30	Moon Seok Choi (Sungkyunkwan Univ., Seoul)
	TOPAZ-1: New Standard of Care in Advanced Cholangiocarcinoma	Do-Youn Oh (Seoul National Univ., Seoul)

 ROOM D Orchid	12:30-13:30	Yoon Jun Kim (Seoul National Univ., Seoul)
	The Role of Abbreviated MRI in the Evolving Landscape of HCC Surveillance	So Yeon Kim (Univ. of Ulsan, Seoul)
	The Evolving Treatment Paradigm of Advanced HCC	Beom Kyung Kim (Yonsei Univ., Seoul)



ORAL POSTER PRESENTATION

ROOM E (Chrysanthemum, 2F)

July 7, 16:20-17:20

Group 1

Jin-Wook Kim (Seoul National Univ.), Jong Eun Yeon (Korea Univ.), Ju Hyun Shim (Univ. of Ulsan)

OP-1	A Better Prognosis of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Receiving Tenofovir Compared with Entecavir <i>Sung Won Chung, University of Ulsan, Korea</i>
OP-2	Comparison of the Effects of Entecavir and Tenofovir Disoproxil Fumarate on Recurrence of Hepatocellular Carcinoma after Surgical Resection in Chronic Hepatitis B <i>Eun Jee Lim, Seoul National University, Korea</i>
OP-3	IMbrave050: Adjuvant Atezolizumab+Bevacizumab VS Active Surveillance in Hepatocellular Carcinoma Patients at High Risk of Disease Recurrence Following Resection or Ablation <i>Han Chu Lee, University of Ulsan, Korea</i>
OP-4	Radiological Response as a Predictor of Overall Survival in Locally Advanced Hepatocellular Carcinoma: Analysis of START-FIT Phase II Trial <i>Chi Leung Chiang, The University of Hong Kong, Hong Kong</i>
OP-5	Integrative Multi-Omics Profiling for Resectable Hepatocellular Carcinoma Uncovers Clinically Available Serum Biomarkers to Predict Microvascular Invasion <i>Incheon Kang, CHA University, Korea</i>
OP-6	Landscape of T-Cell Exhaustion Heterogeneity in Hepatocellular Carcinoma Revealed by Integrating Whole Exome, Transcriptomes, and Single-Cell Sequencing <i>Soon Kyu Lee, The Catholic University of Korea, Korea</i>

Group 2

Chul Ju Han (Korea Cancer Center Hospital), Mi-Suk Park (Yonsei Univ.), Sang Hoon Ahn (Yonsei Univ.)

OP-7	Wild-Type Kirsten Rat Sarcoma (Kras) Promotes Immune Escape via Suppression of Interferon-Mediated Immunity in Hepatocellular Carcinoma <i>Martina Mang Leng Lei, The Hong Kong Polytechnic University, Hong Kong</i>
OP-8	Differential T Cell and Monocyte Responses in Hepatocellular Carcinoma Treated with Regorafenib Plus Nivolumab: A Biomarker Analysis of the Phase 2 RENOBATE Trial <i>Hyung-Don Kim, University of Ulsan, Korea</i>
OP-9	Diagnostic Algorithm for Subcentimeter Hepatocellular Carcinoma Using Alpha-Fetoprotein and Imaging Features on Gadoteric Acid-Enhanced MRI <i>Peng Huang, Fudan University, China</i>
OP-10	Non-Negligible Differences in Radio-Pathologic Characteristics and Prognosis between Subcentimeter and 1-2 cm Hepatocellular Carcinoma <i>Peng Huang, Fudan University, China</i>
OP-11	Non-Contrast Abbreviated MRI (NC-aMRI) VS Contrast-Enhanced (CE-aMRI) for Hepatocellular Carcinoma (HCC) Surveillance among High-Risk Populations-A Meta-Analysis <i>Soe Thiha Maung, Chulalongkorn University, Thailand</i>
OP-12	Machine Learning Classification of Hepatocellular Carcinoma Based on CT Scan Image Using Probabilistic Neural Network Algorithm <i>Rifaldy Fajar, Yogyakarta State University, Indonesia</i>

ORAL POSTER PRESENTATION

ROOM E (Chrysanthemum, 2F)

July 7, 16:20-17:20

Group 3

Tae-Hee Lee (Konyang Univ.), Dongho Choi (Hanyang Univ.), Hyung Joon Kim (Chung-Ang Univ.)

OP-13	Long-Term Outcomes of Liver Transplantation for Patients with Hepatocellular Carcinoma beyond Milan Criteria: A Multicenter Cohort Study <i>Heechul Nam, The Catholic University of Korea, Korea</i>
OP-14	Translational Hepatectomy for Hepatocellular Carcinoma with Inadequate Future-Liver-Remnant after Portal Vein Ligation in Combination with Apatinib Plus Camrelizumab: A Single-Arm Prospective Pilot Study (PLACES) Compared with ALPPS Cohort <i>Tao Peng, Guangxi Medical University, China</i>
OP-15	A MRI-Based Prognostic Stratification System for Medical Decision-Making of Multinodular Hepatocellular Carcinoma Patients: Optimization of the Milan Criteria <i>Fei Wu, Fudan University, China</i>
OP-16	Risk Stratification for Early Recurrence after Resection in Patients with Intermediate Stage Hepatocellular Carcinoma <i>Han Ah Lee, Ewha Womans University, Korea</i>
OP-17	Increased 18F-FDG Uptake of Tumor on PET/CT Predicts Tumor Recurrence in Hepatocellular Carcinoma Patients Undergoing Liver Transplantation <i>Wenjing Zheng, Fudan University, China</i>
OP-18	The Impact of Dynamic Changes in Cachexia Index on the Outcomes after Hepatectomy for Hepatocellular Carcinoma <i>Munetoshi Akaoka, The Jikei University School of Medicine, Japan</i>

Group 4

Byung Ik Kim (Sungkyunkwan Univ.), Mi-Sook Kim (Korea Institute of Radiological & Medical Sciences), Dae Won Jun (Hanyang Univ.)

OP-19	Four-Year Overall Survival (OS) Update from the Phase 3 HIMALAYA Study of Tremelimumab Plus Durvalumab VI in Unresectable Hepatocellular Carcinoma (uHCC) <i>Ghassan K. Abou-Alfa, Memorial Sloan Kettering Cancer Center, USA</i>
OP-20	Survival Outcomes of Out-of-Milan Hepatocellular Carcinoma after Yttrium-90 Selective Internal Radiation Therapy in a Single Institution in Asia <i>Kaina Chen, Singapore General Hospital, Singapore</i>
OP-21	Carbon Ion Radiation Therapy as a Local Salvage Treatment for Recurrent or Residual Hepatocellular Carcinoma Following Transarterial Chemoembolization <i>Kei Shibuya, Gunma University, Japan</i>
OP-22	Silencing of CircRNA-0033351 Represses Hepatic Stellate Cells Activation and Cytokine Storm Induced by Radiation Therapy for Primary Liver Cancer <i>Hao Niu, Fudan University, China</i>
OP-23	Performance and Effectiveness of Hepatocellular Carcinoma Screening in Individuals with HBsAg Seropositivity in China: A Multi-Center Population-Based Prospective Study <i>Jian Zhou, Fudan University, China</i>
OP-24	Soluble Programmed Cell Death-1 as a Predictor of Hepatocellular Carcinoma Development during Nucleoside Analogue Treatment <i>Masaru Enomoto, Osaka Metropolitan University, Japan</i>

Liver Cancer - Epidemiology and Surveillance

PE-1	Exploring Prognostic Disparities of HCC Treatment in the Elderly: An Analysis of the Korean Nationwide Cancer Registry Data <i>Ha Il Kim, Hanyang University, Korea</i>
PE-2	Compliance of Screening of Hepatocellular Carcinoma in Patients with Chronic Viral Hepatitis <i>Won Sohn, Sungkyunkwan University, Korea</i>
PE-3	Impact of Newly Detected Diabetes by OGTT on Development of HCC <i>Seong Hee Kang, Korea University, Korea</i>
PE-4	Do People with Liver Cancer Also Get a Financial Burden <i>Putri Ayu, Andalas University, Indonesia</i>
PE-5	Is It True That Religiosity Increases Survival Rate in Patients with Liver Failure? <i>Lintong Hottua Simbolon, University of Lampung, Indonesia</i>
PE-6	Azathioprine on Risk of Extrahepatic Malignancy in Patients with Autoimmune Hepatitis: A Nationwide Claims Study in South Korea <i>Sung Hwan Yoo, Yonsei University, Korea</i>
PE-7	Utilization of Community-Based Health Centers (Puskesmas) to Improve Accessibility of Health Services for Liver Patients <i>Rosinta Hotmaida Pebrianti Purba, Universitas Gadjah Mada, Indonesia</i>
PE-8	Diagnosis of Intrahepatic Cholangiocarcinoma, Poorly Differentiated Signet Ring Cell Subtype: A Case Report in the Philippines <i>Christian Jorge, Makati Medical Center, Philippines</i>
PE-9	Financial Burden of Liver Cancer: Problem and Solution for Liver Cancer Patient <i>Fitri Kurnia, Universitas Muhammadiyah Sumatera Barat, Indonesia</i>
PE-10	The Changing Pathogenesis of Liver Cancer in Hawaii over Three Decades <i>Larry Hromalik, University of Hawaii, USA</i>
PE-11	Relationship between Coffee Consumption, Hepatic Cancers in Metro City Population <i>Sumit Rajput, Bharati Vidyapeeth Deemed University, India</i>
PE-12	Recurrence Rate-Based Strategy to Tailor Surveillance Scheduling in Single Hepatocellular Carcinoma ≤ 2 cm after Curative Therapy: Analysis of 6,105 Global Patients <i>Ming Zhao, Sun Yat-Sen University, China</i>
PE-13	Preventable Death from Liver Cancer <i>Lyazzat Kosherbayeva, Asfendiyarov Kazakh National Medical University, Kazakhstan</i>
PE-14	Surveillance of Hepatocellular Carcinoma Is Cost-Effective in Chronic Viral Hepatitis Patients in Korea <i>Young Youn Cho, Chung-Ang University, Korea</i>

E-POSTER EXHIBITION

Liver Cancer - Diagnosis and Liver Imaging	
PE-15	The Relationship between Dental Health and Liver Cancer Risk <i>Syafri Suardi, Universitas Muslim Indonesia, Indonesia</i>
PE-16	Assessment of Liver Function Test in Vegetarian and Non-Vegetarian <i>Santosh Gupta, Pokhara University, Nepal</i>
PE-17	Gd-EOB-DTPA Binding T1 Mapping Phase Show Potential to Be a Way to Evaluate Per-Unit Liver Function <i>Yuchen Yang, Shanghai Jiao Tong University, China</i>
PE-18	Sociodemographic and Clinical Factors Associated with Ultrasound LI-RADS Visualization Scores <i>Sera Kim, University of San Francisco, USA</i>
PE-19	Intraindividual Comparison of MRIs with Extracellular and Hepatobiliary Contrast Agents for the Noninvasive Diagnosis of Hepatocellular Carcinoma Using the Korean Liver Cancer Association-National Cancer Center 2022 Criteria <i>Sunyoung Lee, Yonsei University, Korea</i>
PE-20	Mass-Forming Intrahepatic Cholangiocarcinoma: Preoperative Subcategorization Based on Magnetic Resonance Imaging <i>Yuyao Xiao, Fudan University, China</i>
PE-21	Combined Hepatocellular Carcinoma-Cholangiocarcinoma: HCC Percentage Higher than 65% Predicted by Preoperative MR Features Is Prognostic <i>Yuyao Xiao, Fudan University, China</i>
PE-22	Extra-Hepatic Feeding Artery: An Imaging Feature Predicts Prognosis of Hepatocellular Carcinoma <i>Cheng Wang, Fudan University, China</i>
PE-23	Clear Cell Hepatocellular Carcinoma: Gadoteric Acid-Enhanced MR Imaging Features and Prognosis <i>Mingyue Song, Soochow University, China</i>
PE-24	Distinct Radiological Features of Intrahepatic Lymphoepithelioma-Like Cholangiocarcinoma: Comparison with Classical Intrahepatic Cholangiocarcinoma <i>Gengyun Miao, Fudan University, China</i>
PE-25	Is It Necessary to Distinguish between cHCC-CCA Cases with Less than 10% of CCA Components and HCC Cases? <i>Changwu Zhou, Fudan University, China</i>

E-POSTER EXHIBITION

Liver Cancer - Staging and Prognosis

PE-26	Proper Position of Single and Large (≥ 5 cm) Hepatocellular Carcinoma in Barcelona Clinic Liver Cancer Classification <i>Hyo-Sin Kim, Chonnam National University, Korea</i>
PE-27	Similar Recurrence after Curative Treatment of HBV-Related HCC Regardless of HBV Replication Activity <i>Mi Na Kim, Yonsei University, Korea</i>
PE-28	The Efficacy of Biliary Drainage in HCC with Bile Duct Invasion: A Multicenter Retrospective Cohort Study <i>Keungmo Yang, The Catholic University of Korea, Korea</i>
PE-29	A Novel Nomogram for Prediction of Progression Free Survival after Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma <i>Qi-Qiao Wu, Fudan University, China</i>
PE-30	New Preoperative CT Staging of Intrahepatic Cholangiocarcinoma: Impact of Up-Staging of Tumor Multiplicity on Survival Outcomes <i>Yeun-Yoon Kim, Sungkyunkwan University, Korea</i>
PE-31	Development of a Prognostic Scoring System for Hepatocellular Carcinoma with Hepatic Vena Cava Budd-Chiari Syndrome <i>Xiaowei Dang, Zhengzhou University, China</i>
PE-32	Study of New Methods for Analyzes and Monitor of Health Data in Relation to Hepatocellular Carcinoma Survivors Patients via Wearable Technology <i>Vikas Sharma, Sarojini Naidu Medical College, India</i>
PE-33	Estimating Microvascular Invasion in Patients with Resectable Multinodular Hepatocellular Carcinoma by Using Preoperative Contrast-Enhanced MRI: Development and Validation of a Risk Score <i>Fei Wu, Fudan University, China</i>

Liver Cancer - Biomarkers

PE-34	Expression of Cancer Stem Cell Markers Cluster Differentiation 44 (CD44), CD90, CD133, Epithelial Cells Adhesion Molecule (EpCAM) and Alpha-Fetoprotein (AFP) Serum Level in Patients with Advanced Liver Disease <i>Syifa Mustika, Universitas Brawijaya, Indonesia</i>
PE-35	Association of Circulating Lymphocyte with Progression-Free Survival for Patients with Recurrent Hepatocellular Carcinoma Who Received Stereotactic Body Radiotherapy Combined with Anti-PD-1 Therapy <i>Yuan Zhuang, Fudan University, China</i>
PE-36	Some Clinical and Subclinical Characteristics on HCC Patients <i>Le Thi Thu Hien, Thai Nguyen University, Vietnam</i>
PE-37	Comprehensive Analysis of Expression, Prognostic Value and Immune Infiltration for LMNB1 in Hepatocellular Carcinoma <i>Xiaowei Dang, Zhengzhou University, China</i>

Liver Cancer - Molecular Pathogenesis and Pathology

PE-38	Lenvatinib Induced Cell Death of Hepatocellular Carcinoma by Increasing HIF- α Degradation under Hypoxic Condition <i>Sung Won Chung, University of Ulsan, Korea</i>
PE-39	Bile Acid-Mediated Induction of Hepatic Stellate Cell Activation Enhances the Invasion of Hepatocellular Carcinoma via Mcl-1 and COX-2 <i>Yuri Cho, National Cancer Center Korea, Korea</i>
PE-40	Biological Potential and Therapeutic Effectiveness of Magnolin for the Treatment of Hepatocellular Carcinoma <i>Kanika Patel, Sam Higginbottom University of Agriculture, India</i>
PE-41	Clinico-Pathological Characterization of hTERT-Telomere Abnormalities in Hepatocellular Carcinoma <i>Jeong Eun Jang, The Catholic University of Korea, Korea</i>
PE-42	Therapeutic Benefit and Biological Potential of Tricetin on Liver Cancer: Biological Application in the Health Sectors <i>Dinesh Kumar Patel, Sam Higginbottom University of Agriculture, India</i>
PE-43	Mesenchymal Tumor of the Liver in an Eight-Year Old Filipino Child <i>Gladys Larissa V. Armada, Philippine Children's Medical Center, Philippines</i>
PE-44	Genomic and Histopathological Landscape of Premalignant Papillary Neoplasms of Human Biliary System <i>Taek Chung, Yonsei University, Korea</i>
PE-45	Fibronectin Expression Correlates with Microvascular Invasion in Hepatocellular Carcinoma <i>Yoon Jung Hwang, Seoul National University, Korea</i>
PE-46	Correlation between CTNNB1 Mutation Status and Tumor Phenotype in Hepatitis B Virus-Related Hepatocellular Carcinoma <i>Yoon Jung Hwang, Seoul National University, Korea</i>

Liver Cancer - Treatment: Clinical Trials

PE- 47	Clinical Trial in Asian Patients Liver Cancer: Systematic Review <i>Ferza Alfath, Universitas Andalas, Indonesia</i>
PE-48	Comparison of Background Characteristics of Patients Receiving Lenvatinib VS Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma <i>Shinji Itoh, Kyushu University, Japan</i>
PE-49	Neoadjuvant Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Plus Transhepatic Arterial Infusion Chemotherapy (HAIC) with FOLFOX for Resectable Multinodular CNLC I b/II a Hepatocellular Carcinoma <i>Tao Peng, Guangxi Medical University, China</i>

Liver Cancer - Treatment: Surgical Resection and Transplantation

PE-50	A Systematic Review on Live Donor Liver Transplantation (LDLT) in Asia <i>Devi Yulia Rahmi, Universitas Andalas, Indonesia</i>
PE-51	Comparison of Open versus Laparoscopic Approaches in Salvage Hepatectomy for Recurrent Hepatocellular Carcinoma after Radiofrequency Ablation <i>Yeshong Park, Seoul National University, Korea</i>
PE-52	Immunosuppression after Liver Transplantation <i>Nurzhan Yerniyazov, Kyzylorda City Oncology Center, Kazakhstan</i>
PE-53	Surgical Tactics of Treatment of Liver Hemangiomas <i>Rokiyta Surova, Kyrgyz State Medical Academy, Kyrgyzstan</i>
PE-54	Laparoscopic Drainage Basin Hepatectomy Based on Cone Unit <i>Yu Cheng, Binzhou Medical University, China</i>
PE-55	Medical Tourism for Liver Transplantation in Patients with Hepatocellular Carcinoma: A Systematic Review of the Opportunity, Risks and Benefits <i>Nissa Larasati, Universitas Gadjah Mada, Indonesia</i>
PE-56	Multidimensional Quality of Life after Pediatric Liver Transplantation: Luck or Measurable Achievement? <i>Hepri Ardianson Purba, University of Lampung, Indonesia</i>
PE-57	Sexual Function Deterioration among Donor and Recipients of Living Donor Liver Transplantation (LDLT) a Systematic Review <i>Hepri Ardianson Purba, University of Lampung, Indonesia</i>
PE-58	Analysis of Recurrence Pattern after Partial Hepatectomies for Hepatocellular Carcinoma <i>Ming-Chin Yu, New Taipei Municipal Tucheng Hospital, Taiwan</i>
PE-59	Immediate Results of Surgical Treatment Cholangiocellular Cancer <i>Surov Edir, Kyrgyz-Russian Slavic University, Kyrgyzstan</i>
PE-60	Laparoscopic Liver Echinococcectomy <i>Kulmaganbetov Aidos, Kyzylorda City Regional Medical Center, Kazakhstan</i>
PE-61	Immediate Results of Surgical Treatment Hepatocellular Cancer <i>Begimai Murzalieva, Kyrgyz State Medical University, Kyrgyzstan</i>
PE-62	Surgical Tactics for Colorectal Cancer with Synchronous Liver Metastases <i>Erlan Murzaliev, Kyrgyz-Russian Slavic University, Kyrgyzstan</i>
PE-63	Enucleation of Dysplastic Nodule Segment 7 in Child B Liver Cirrhosis <i>Muhammad Zakria, Evercare Hospital Lahore, Pakistan</i>

E-POSTER EXHIBITION

Liver Cancer - Treatment: Surgical Resection and Transplantation	
PE-64	<p>Living Donor Liver Transplantation in Children</p> <p><i>Nuraliah, West Sulawesi Research and Empowerment Center, Indonesia</i></p>
PE-65	<p>Effects of Livact Granule on Liver Function Recovery after Donor Right Hemi-Hepatectomy</p> <p><i>Ho Joong Choi, The Catholic University of Korea, Korea</i></p>
PE-66	<p>Economical Analysis of the Routine Use of Thromboelastography (TEG) to Analyze Blood Component Needed in Liver Transplant Patients</p> <p><i>Ninda Devita, Universitas Islam Indonesia, Indonesia</i></p>
PE-67	<p>Tumor Thrombectomy via Surgically Reopened Umbilical Vein as a Palliative Treatment for Patient with Advanced Hepatocellular Carcinoma</p> <p><i>Nguyen Truong Giang, National Hospital of Tropical Diseases, Vietnam</i></p>
PE-68	<p>Anatomical Liver Resection Sparing Ventral or Dorsal Part of Right Anterior Sector for Patient with Hepatocellular Carcinoma: A Surgical Team's Experience.</p> <p><i>Nguyen Truong Giang, National Hospital of Tropical Diseases, Vietnam</i></p>
PE-69	<p>Impact of Frailty on Long-Term Outcomes after Liver Resection for Hepatocellular Carcinoma in Elderly Patients</p> <p><i>Shogo Tanaka, Izumi City General Hospital, Japan</i></p>
PE-70	<p>Anatomic versus Non-Anatomic Resection for Early-Stage Intrahepatic Cholangiocarcinoma: A Multicentric Case-Matched Study from China</p> <p><i>Qiao Ke, Fujian Medical University, China</i></p>
PE-71	<p>Narrow Surgical Margin Does Not Influence the Prognosis of Solitary Hepatocellular Carcinoma: A Real-World Study from China</p> <p><i>Qiao Ke, Fujian Medical University, China</i></p>
PE-72	<p>Anatomic versus Non-Anatomic Resection for Patients with Hepatocellular Carcinoma and Microvascular Invasion: A Systematic Review and Meta-Analysis</p> <p><i>Qiao Ke, Fujian Medical University, China</i></p>
PE-73	<p>JSC National Scientific Center of Oncology and Transplantation</p> <p><i>Aidar Zulkhanay, JSC National Scientific Center, Kazakhstan</i></p>
PE-74	<p>Portal Vein Thrombosis in Patients with End-Stage Liver Disease on the Waiting List</p> <p><i>Nazerke Seidakhmetova, Aqtobe City Regional Hospital, Kazakhstan</i></p>
PE-75	<p>Human Fetal Liver Cells as a Bridge to the Liver Transplantation in Patients Waiting for Donors</p> <p><i>Akhmet Seidakhmetov, Republic Coordination Center for Transplantation and Hi-tech Services, Kazakhstan</i></p>
PE-76	<p>Long-Term Surgical Outcomes for Non-Alcoholic Fatty Liver Disease Associated Hepatocellular Carcinoma</p> <p><i>Jai Young Cho, Seoul National University, Korea</i></p>

E-POSTER EXHIBITION

Liver Cancer - Treatment: Transarterial Approach/Percutaneous Ablative Therapy/Radiation Therapy

PE-77	Feasibility and Efficacy of Repeated Stereotactic Body Radiotherapy for Recurrent Hepatocellular Carcinoma <i>Won Il Jang, Korea Institute of Radiological and Medical Sciences</i>
PE-78	Trends of Radiotherapy in the Management of Elderly Patients with Hepatocellular Carcinoma <i>Jeong Il Yu, Sungkyunkwan University, Korea</i>
PE-79	Feasibility of Additional Radiotherapy for Advanced Hepatocellular Carcinoma Patients Treated with Atezolizumab Plus Bevacizumab <i>Tae Hyun Kim, National Cancer Center Korea, Korea</i>
PE-80	Poor Clinical Outcome of Deep-Seated Hepatocellular Carcinoma after Radiofrequency Ablation <i>Gwang Hyeon Choi, Seoul National University, Korea</i>
PE-81	Prognostic Performance of the China Liver Cancer Staging System in Hepatocellular Carcinoma Following Transarterial Chemoembolization <i>Bin-Yan Zhong, Soochow University, China</i>
PE-82	Radioembolization-Induced Liver Disease (REILD) in Hepatocellular Carcinoma (HCC) Patients after Treatment with Yttrium-90 (Y90)-A Retrospective Cohort Study <i>Yeo Eng Xuan, National University of Singapore, Singapore</i>
PE-83	A Propensity Score Analysis of Surgical Resection and Yttrium 90 Radioembolization in Hepatocellular Carcinoma Patients with Portal Vein Tumour Thrombosis <i>Zou Zhaozhen, Duke-National University Singapore Medical School, Singapore</i>
PE-84	Oncology <i>Yu Yin, Soochow University, China</i>
PE-85	Safety and Efficacy of Sequential Hepatic Arterial Infusion Chemotherapy and Transarterial Embolization for Unresectable Hepatocellular Carcinoma <i>Jun Yang, Soochow University, China</i>
PE-86	The Value of Preoperative Hepatic Vein Embolization Combined with Precise TACE in Stage II Resection of Primary Liver Cancer <i>Lianxin Liu, University of Science and Technology of China, China</i>
PE-87	Dose the Tumor Marker Regression Predict the Survival after External Beam Radiotherapy in Hepatocellular Carcinoma? <i>Won Sup Yoon, Korea University, Korea</i>
PE-88	Effects of Stereotactic Body Radiotherapy versus Conventional Fractionated Radiotherapy on Circulating Lymphocyte Levels in Patients with Hepatocellular Carcinoma <i>Yuan Zhuang, Fudan University, China</i>
PE-89	An Investigation into the Development of Radiation Pneumonitis Following Yttrium-90 Selective Internal Radiation Therapy in a Single Institution in Asia: A Retrospective Cohort Study <i>Ong Sheng Khai Timothy, National University of Singapore, Singapore</i>
PE-90	Clinical Outcomes of Stereotactic Body Radiation Therapy Alone versus Stereotactic Body Radiation Therapy after Incomplete Transarterial Chemoembolization for a Single Small (≤ 5 cm) Recurrent Hepatocellular Carcinoma <i>Jin-Hong Park, University of Ulsan, Korea</i>

E-POSTER EXHIBITION

Liver Cancer - Treatment: Transarterial Approach/Percutaneous Ablative Therapy/Radiation Therapy

PE-91	Efficacy and Safety of Small-Size Drug-Eluting Beads Transcatheter Arterial Chemoembolization Combined with Lenvatinib for Unresectable Hepatocellular Carcinoma <i>Jun Deng, China Medical University, China</i>
PE-92	Liver Acute Cytolysis after Transarterial Chemoembolization in Hepatocellular Carcinoma <i>Tsakhim-Erdene Tsendjav, Mongolian National University, Mongolia</i>
PE-93	Prediction of Early Treatment Response to Initial Conventional Transarterial Chemoembolization for Caudate Lobe Hepatocellular Carcinoma: A Retrospective Study <i>Xinying Song, China Medical University, China</i>
PE-94	Comparison of Dosimetry Models to Predict Outcome for Radioembolization in Patients with Intermediate to Advanced Hepatocellular Carcinoma <i>Hui-Chi Liu, National Taiwan University, Taiwan</i>
PE-95	Curative-Dose Radiotherapy and Multiagent Chemotherapy Improves Survival of Locally Advanced Intrahepatic Cholangiocarcinoma: A Multi-Institutional Cohort Study <i>Jung Ho Im, CHA University, Korea</i>
PE-96	Liver-Directed Combined Radiotherapy for Downstaging of over the Milan Hepatocellular Carcinoma Converting to Liver Transplantation <i>Yong Tae Kim, Yonsei University, Korea</i>
PE-97	Combined Radiotherapy, Anti-Angiogenesis and Immune Checkpoint Blockade Inhibition of Portal Vein Tumor Thrombus in Hepatocellular Carcinoma <i>Keren Li, Tsinghua University, China</i>
PE-98	Olaparib Contributes to Radiation Induced Primary and Abscopal Tumor Control by Activating STING-Dependent Innate Immune Response <i>Genwen Chen, Fudan University, China</i>
PE-99	Prognostic Significance of Platelet-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Undergoing Curative Radiation Therapy <i>Dong Soo Lee, The Catholic University of Korea, Korea</i>
PE-100	External Beam Radiotherapy in Patients with Advanced Hepatocellular Carcinoma Presenting Bile Duct Invasion <i>Sang Min Yoon, University of Ulsan, Korea</i>
PE-101	Efficacy of Liver-Directed Combined Radiotherapy in Locally Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis <i>Jina Kim, Yonsei University, Korea</i>
PE-102	A Refined Prediction Model for Overall Survival in Patients Undergoing Transarterial Chemoembolization for Hepatocellular Carcinoma <i>Hae Lim Lee, The Catholic University of Korea, Korea</i>

E-POSTER EXHIBITION

Liver Cancer - Treatment: Systemic Therapy / Targeted Therapy / Immunotherapy	
PE-103	Real-World Experience of Atezolizumab Plus Bevacizumab Combination Treatment in High-Risk Patients with Advanced Hepatocellular Carcinoma <i>Jeong Heo, Pusan National University, Korea</i>
PE-104	Risk of Gastrointestinal Bleeding in Patients Receiving Atezolizumab–Bevacizumab Treatment for Hepatocellular Carcinoma <i>Kanghee Park, University of Ulsan, Korea</i>
PE-105	Case Reports: Advanced Hepatocellular Carcinoma Patients Treated with Atezolizumab and Bevacizumab Develop Brain Hemorrhages <i>Bang Ju Kim, Kosin University, Korea</i>
PE-106	Lung-Specific Response to Atezolizumab Plus Bevacizumab Is Associated with Overall Survival in Patients with Lung Metastasis from Hepatocellular Carcinoma <i>Jiwon Yang, University of Ulsan, Korea</i>
PE-107	Effectiveness and Safety of Sorafenib 400mg Initial Dose Compared with Sorafenib 800mg Initial Dose on Survival in Patients with Advanced and Intermediate Stage Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis <i>Roland Helmizar, Baiturrahmah University, Indonesia</i>
PE-108	Efficacy and Safety of 5-Fluorouracil-Oxaliplatin with Ramucirumab in Patients with Advanced Hepatocellular Carcinoma: A Case Series <i>Joycelyn Jie Xin Lee, National Cancer Centre Singapore, Singapore</i>
PE-109	Real-World Efficacy and Safety of Cabozantinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Analysis <i>Yeong Hak Bang, University of Ulsan, Korea</i>
PE-110	Radiotherapy Combined with Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus <i>Yunjeong Lee, Seoul National University, Korea</i>
PE-111	Changes in Splenic Volume as a Predictor of Response and Survival in Advanced Hepatocellular Carcinoma Patients Receiving Immunotherapy or Sorafenib <i>Bang-Bin Chen, National Taiwan University, Taiwan</i>
PE-112	A Real-World Comparative Analysis of Atezolizumab Plus Bevacizumab and Transarterial Chemoembolization Plus Radiotherapy in Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombosis <i>Soon Kyu Lee, The Catholic University of Korea, Korea</i>
PE-113	Is Modified Albumin-Bilirubin (mALBI) Grade Prognostic for All Hepatocellular Carcinoma Patients Who Receive Systemic Treatment? <i>Kevin Mok, Prince of Wales Hospital, Hong Kong</i>
PE-114	Real-World Outcomes of Patients with Unresectable Intrahepatic Cholangiocarcinoma Treated with Radiotherapy, Lenvatinib, Anti-PD-1 Antibody, and GEMOX Chemotherapy <i>Qianqian Zhao, Fudan University, China</i>
PE-115	Hepatic Arterial Infusion Chemotherapy Combined with Anti-PD-1 /PD-L1 Immunotherapy and Molecularly Targeted Agents for Advanced Hepatocellular Carcinoma: A Real World Study in China <i>Kai Zhang, Tianjin Medical University, China</i>

E-POSTER EXHIBITION

Liver Cancer - Treatment: Systemic Therapy / Targeted Therapy / Immunotherapy	
PE-116	Final Results of RENOBATE: Multicenter Phase 2 Trial of First-Line Regorafenib Plus Nivolumab for Unresectable Hepatocellular Carcinoma (uHCC) <i>Hyung-Don Kim, University of Ulsan, Korea</i>
PE-117	Effectiveness and Safety of Lenvatinib, a PD-1 Inhibitor Plus Radiotherapy, in Patients with Hepatocellular Carcinoma with Main Portal Vein Tumour Thrombus: Real-World Experience from a Tertiary Center <i>Guang Xin Li, Tsinghua University, China</i>
PE-118	Arterial Chemotherapy in Advanced Hepatocellular Carcinoma: An Evolutionary Trajectory, Pooled Outcomes and Cost-Effectiveness Analysis <i>Ming Zhao, Sun Yat-Sen University, China</i>
PE-119	Efficacy and Safety of Lenvatinib in Patients with Recurrent Hepatocellular Carcinoma after Liver Transplantation <i>Kyunghye Bang, Chung-Ang University, Korea</i>
PE-120	Clinical Outcomes of Immune Checkpoint Inhibitors in Unresectable or Metastatic Combined Hepatocellular-Cholangiocarcinoma <i>Yoon Jung Jang, Korea Cancer Center Hospital, Korea</i>
PE-121	Analysis of Immune-Related Adverse Events and Time-to-Treatment Discontinuation of Atezolizumab and Bevacizumab in Patients with Hepatocellular Carcinoma: A Multicenter Cohort Study <i>Heechul Nam, The Catholic University of Korea, Korea</i>
PE-122	Sarcopenia Predicts Outcomes in Patients with Hepatocellular Carcinoma Treated with Atezolizumab and Bevacizumab: A Multicenter Cohort Study <i>Heechul Nam, The Catholic University of Korea, Korea</i>

Liver Cancer - Treatment: Novel Target or Experimental Therapy	
PE-123	Multimodal Integrative Genomics and Pathology Analyses in Neoadjuvant Nivolumab Treatment for Borderline Resectable HCC <i>Tan To Cheung, The University of Hong Kong, Hong Kong</i>
PE-124	Comparison of Anti-Thrombotic Activity of Known Medicinal Herbs on P2P12 Receptor: An In-Silico Approach <i>Dhananjay Yadav, Yeungnam University, Korea</i>
PE-125	Immunotherapy Resistance <i>Gui-Qi Zhu, Fudan University, China</i>
PE-126	Liquid Crystalline Nanoparticles (LCNPS) Based Delivery of an Anticancer Bioactive, Methotrexate <i>Mani Bhargava, Signa College of Pharmacy, India</i>
PE-127	Galactose Conjugated PPI Dendrimers for Liver Targeting <i>Saurabh Bhargava, United Institute of Pharmacy, India</i>

Liver Cancer - Cell Biology and Translational Research

PE-128	Molecular Docking as a Therapeutic Approach for Targeting Hepatocellular Carcinoma Cells <i>Preeti Puranik, Shri Jain Diwakar Mahavidyalaya, India</i>
PE-129	Non-Coding and Coding RNA Regulatory Network for Early Diagnosis of Liver Cancer <i>Nidhi Puranik, Yeungnam University, Korea</i>
PE-130	Interleukin-1b -511C>T Gene Polymorphisms and Its Association with HBV Infection-Associated Hepatocellular Cell Carcinoma Susceptibility: A Systematic Review and Meta-Analysis <i>Indah Sagitaisna Putri, Sebelas Maret University, Indonesia</i>
PE-131	Identification of Macrophage Associated Gene Landscape to Evaluate Immune Infiltration and Therapeutic Response in Hepatocellular Carcinoma <i>Tong Li, Fudan University, China</i>
PE-132	METTL3-Mediated STING Upregulation and Activation in Kupffer Cells Contribute to Radiation Induced Liver Disease via Pyroptosis <i>Biao Wang, Fudan University, China</i>
PE-133	Antitumorigenic Effect of Silver Nanoparticle in Experimental Liver Cancer Rat Model <i>Ankush Kumar, A State University, India</i>
PE-134	Role of Micro-RNA Gene Polymorphisms in Egyptian Patients Who Developed Hepatocellular Carcinoma <i>Abdel Ghani Badran, Specialized Medical Center-Damas Liver Center, Egypt</i>
PE-135	MiR-34a Inhibits Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma by Targeting CDH13 <i>Zhang Li, Fudan University, China</i>
PE-136	Efficacy of X-Ray Irradiation in Combination with CCR5 Antagonist for Hepatocellular Carcinoma in C57BL/6J Mice <i>Yi-Xing Chen, Fudan University, China</i>
PE-137	Biological Importance of Calycopterin against Human Hepatoblastoma Cancer through Different Molecular Mechanism: Therapeutic Importance in the Medicine <i>Dinesh Kumar Patel, Sam Higginbottom University of Agriculture, India</i>
PE-138	Sorafenib Combined with Dickkopf-1 Inhibitor Synergistically Inhibited PI3K/Akt and Wnt/ β -Catenin Signaling Pathways in Hepatocellular Carcinoma <i>Sang Hyun Seo, Yonsei University, Korea</i>
PE-139	Beneficial Potential of Photodynamic Therapy and Chemotherapy in Murine Liver Cancer Cells <i>Pardeep Kumar, F H Medical College, India</i>
PE-140	Akkermansia Muciniphila Regulates Development and Immune Resistance of Non-Alcoholic Fatty Liver Disease (NAFLD)-Induced Hepatocellular Carcinoma <i>Terence Kin Wah Lee, The Hong Kong Polytechnic University, Hong Kong</i>
PE-141	DGKH as a Novel Metabolic Driver of Cancer Stemness and Therapy Resistance in Hepatocellular Carcinoma <i>Jia Jian Loh, The University of Hong Kong, Hong Kong</i>

E-POSTER EXHIBITION

Liver Cancer - Cell Biology and Translational Research	
PE-142	Cancer Stem Cell <i>Huqian Yu, The University of Hong Kong, Hong Kong</i>
PE-143	Targeting SPINK1 Overcomes Chemoresistance through Reshaping Cellular Plasticity in Hepatocellular Carcinoma <i>Ki-Fong Man, The University of Hong Kong, Hong Kong</i>
PE-144	Isolation of Tumor Endothelial Cells from Human Hepatocellular Carcinoma and Functional Analysis of Intercellular Interaction <i>Mitsuru Yanagaki, The Jikei University School of Medicine, Japan</i>

Liver Cancer - AI	
PE-145	Developing of Artificial Intelligence on Liver Cancer: Systematic Review <i>Muhammad Irzaq, Padang State University, Indonesia</i>
PE-146	Which Is Better? Robot-Assisted Liver Surgery (ROBR) or Laparoscopic Liver Resection (LAPR): Systematic Literature Review <i>Zulfa Saumia, Universitas Jambi, Indonesia</i>
PE-147	Artificial Intelligence (AI)-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes (TILs) as a Predictive Biomarker for Anti-PD-1 in Advanced Biliary Tract Cancer (BTC) <i>Yeong Hak Bang, University of Ulsan, Korea</i>
PE-148	Revolutionizing Cancer Diagnosis and Treatment: Harnessing the Power of Deep Learning Technology for Biomarker Discovery <i>Citra Suardi, Universitas Ciputra Surabaya, Indonesia</i>
PE-149	The Accuracy of Microvascular Invasion Prediction Based on Radiomics Methods in Hepatocellular Carcinoma: A Meta-Analysis of Diagnostics Study <i>Mochamad Afifudin, Islamic University of Indonesia, Indonesia</i>
PE-150	Ultrasound-Based Deep Learning Model for Detection and Classification of Focal Liver Lesions <i>Seung Kak Shin, Gachon University, Korea</i>
PE-151	Multiparametric MRI-Based Deep Learning for Prediction of Microvascular Invasion Status in Intrahepatic Cholangiocarcinoma <i>Xianling Qian, Fudan University, China</i>
PE-152	A Comprehensive Nomogram Based on MRI Radiomics to Predict Microvascular Invasion and Overall Survival in Patients with Intrahepatic Cholangiocarcinoma <i>Gengyun Miao, Fudan University, China</i>

Liver Cancer - Miscellaneous	
PE-153	Outpatient Pattern of Liver Cancer Patients Based on Gate-Keeper System a Case Study of Indonesia <i>Lintong Hottua Simbolon, University of Lampung, Indonesia</i>

Viral Hepatitis

PE-154	Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Following HBsAg Seroclearance <i>Jonggi Choi, University of Ulsan, Korea</i>
PE-155	Viral Hepatitis in Asia: Systematic Review <i>Devi Yulia Rahmi, Universitas Andalas, Indonesia</i>
PE-156	Nucleotide/Nucleoside Analogues Treatment for Chronic Hepatitis B Patients without Cirrhosis and with Low Viral Load <i>Chia-Yen Dai, Kaohsiung Medical University, Taiwan</i>
PE-157	Prevalence of Abnormal LFTs, Pattern of Liver Injury and It's Outcome in Covid-19 Patients - A Study from Tertiary Hospital <i>Zahabia Sohail, The Aga Khan University, Pakistan</i>
PE-158	Oral Combination Vaccine against Hepatitis B & Influenza: Development and Characterization <i>Riya Bhargava, Himalayan University, India</i>
PE-159	Development of Bipolymer Based Novel Nanoparticles in Microsphere System as Vaccine Adjuvant <i>Prakash Gosain, Manav Bharti University, India</i>
PE-160	Solid Lipid Based Nanoparticulate System for Effective Vaccine Delivery <i>Yukti Bhargava, Signa College of Nursing, India</i>
PE-161	Antibody Coated Liposomes for Transmucosal Vaccination <i>Priyanka Gosain, Guru Teg Bahadur Hospital, India</i>
PE-162	QT Prolongation in Patients with Chronic Hepatitis B or C Who Receive Antiviral Therapy: A Cross-Sectional Study <i>Syania Shabrina, Universitas Sebelas Maret, Indonesia</i>
PE-163	Liver Fibrosis Disease Classification Based on Hepatitis C Patient Data Using Extreme Learning Machine Algorithm <i>Rifaldy Fajar, Yogyakarta State University, Indonesia</i>
PE-164	Prognosis of the Course of Cytomegalovirus Hepatitis in Children Caused by the COVID-19 Pandemic <i>Manshuk Bakytzhanova, Astana Medical University, Kazakhstan</i>
PE-165	Comparison of the Prevalence of Hepatitis in Indonesia with Asian Countries <i>Nuraliah, West Sulawesi Research and Empowerment Center, Indonesia</i>
PE-166	Effect of Hepatitis in Pregnancy and Prevention of Transmission to the Fetus <i>Indra Suardi, STIKMAH Tobelo, Indonesia</i>
PE-167	Determination of HBsAg Cut off Index (COI) for Diagnosing Acute Hepatitis B <i>Adika Zhulhi Arjana, Universitas Gadjah Mada, Indonesia</i>

E-POSTER EXHIBITION

Viral Hepatitis	
PE-168	Assessment of Liver Enzymes among the Hepatitis A Virus (HAV) Infected Pediatric Patients in Western Nepal <i>Megh Nath Dahal, Gandaki Medical College Teaching Hospital and Research Centre, Nepal</i>
PE-169	Concomitant Non-Alcoholic Fatty Liver Disease Drives Progression of Overall Liver Disease more than Chronic Hepatitis B Alone in Chinese-Americans <i>Rouchelle D. dela Cruz, The Medical City, Philippines</i>
PE-170	Effectiveness of Phyllanthus Urinaria Leaves Combined with Tenofovir in Treatment of Chronic Hepatitis B <i>Le Thi Thu Hien, Thai Nguyen University, Vietnam</i>
PE-171	Indicator of Inflammation: A Case Control Study on C-Reactive Protein (CRP) in Hepatitis Infected <i>Suresh Jaiswal, Pokhara University, Nepal</i>
PE-172	C-Reactive Protein (CRP) as an Inflammatory Marker: A Case Control Study on Hepatitis Infected Individuals <i>Sabina Gaihre, Pokhara University, Nepal</i>
PE-173	Utilization of UKS in Preventing the Spread of Acute Hepatitis in Elementary School Students in Indonesia <i>Ardela Iga Pratiwi, Universitas Gadjah Mada, Indonesia</i>


Cirrhosis and Related Complications	
PE-174	The Impact of a Mass Transfusion Protocol on the Outcome of Patients with Acute Variceal Bleeding: Propensity Score-Matched Analysis <i>Aryoung Kim, Sungkyunkwan University, Korea</i>
PE-175	Recurrence of Portosystemic Encephalopathy in Cirrhotic Patients and Its Risk Factors <i>Zahabia Sohail, The Aga Khan University, Pakistan</i>
PE-176	Study of Selected Natural Phytomedicines Used in the Treatment of Liver Fibrosis Targeting TGF- β Protein <i>Dhananjay Yadav, Yeungnam University, Korea</i>
PE-177	Hydrothorax Treatment in Patients with Liver Cirrhosis <i>Symbat Kulmaganbetova, Kyzylorda Oncology Center, Kazakhstan</i>
PE-178	Bioactivities and Hepatoprotective Effects of Flavonoid Pectolarin in the Management of Liver Disorders: A Phototherapeutic Approach in the Medicine <i>Dinesh Kumar Patel, Sam Higginbottom University of Agriculture, India</i>
PE-179	Biological Potential and Hepatoprotective Activity of Tectoridin on the Human Liver System: Molecular Mechanism and Scientific Data Analysis <i>Dinesh Kumar Patel, Sam Higginbottom University of Agriculture, India</i>
PE-180	Therapeutic Importance of Hispidulin against Nonalcoholic Fatty Liver Disease (NAFLD): Biological Importance in the Medicine <i>Dinesh Kumar Patel, Sam Higginbottom University of Agriculture, India</i>

E-POSTER EXHIBITION

Cirrhosis and Related Complications	
PE-181	Validation of Baveno-VII Criteria for Clinically Significant Portal Hypertension in Patients with Compensated Advanced Chronic Liver Disease <i>Byeong Geun Song, Sungkyunkwan University, Korea</i>
PE-182	The Performance of CRP to Albumin Ratio in Predicting Mortality of HBV-Related Decompensated Cirrhosis: A Meta-Analysis <i>Adika Zhulhi Arjana, Universitas Gadjah Mada, Indonesia</i>
PE-183	Fetal Liver Stem Cells in Combination with Pancreas Cells as an Alternative Treatment in Patients with Liver Cirrhosis, Complicated by Diabetes Mellitus <i>Serkulov Alibek, Transplant Coordinating Center, Kazakhstan</i>
PE-184	Non Invasive Detection of Esophageal Varices in Patients with Compensated Liver Cirrhosis <i>Mohamed Abdel-Samiee, Menoufia University, Egypt</i>
PE-185	Sudoscan for Detection of Small Fiber Neuropathy Changes in Hepatitis C Virus Infected Cirrhotic Patients <i>Mohamed Abdel-Samiee, Menoufia University, Egypt</i>
PE-186	Beneficial Effect of White Sesame Oil on Lipid Profile and Liver Enzymes in Male Rats Treated against Thioacetamide-Induced Hepatotoxicity <i>Ankush Kumar, A State University, India</i>
PE-187	The Effect of Liver Cirrhosis on the Mental Condition of Elderly Patients <i>Ardela Iga Pratiwi, Universitas Gadjah Mada, Indonesia</i>

Other Hepatobiliary Diseases	
PE-188	Metformin Ameliorates Liver Fibrosis Induced by Congestive Hepatopathy via mTOR/HIF-1 α Signaling Pathway <i>Xiaowei Dang, Zhengzhou University, China</i>
PE-189	Rare Presentation of a Multicystic Biliary Tumour with Features of a Biliary Adenofibroma <i>Leow Wei Qiang, Singapore General Hospital, Singapore</i>

MEMO



2023

APPLE

The Asia-Pacific Primary Liver Cancer Expert Meeting

Hosting Organization



Our Partners

Diamond



Gold



Silver Plus



Silver

BORYUNG



Bronze



abbvie

Blue



Supporting Organization



www.apple2023.org

PLEASE SCAN THE QR CODE BELOW.



Abstract Book Download



2023
APPLE

The Asia-Pacific Primary Liver Cancer Expert Meeting